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ABSTRACT
The Group A streptococcus (GAS) produces millions of infections worldwide, leading to
acute diseases, post-infection sequelae, and severe complications. This leading human pathogen
requires iron for growth and relies on the heme-iron it obtains from host hemoproteins to fulfill its
need for the metal during infection. Since heme is a critical nutrient for GAS within the host
environment, the proteins involved in heme capture and metabolism could be targeted for the
development of new modalities to treat and prevent GAS infections and their devastating
complications. The 10-gene sia operon, which consists of two surface receptors (Shr and Shp), and
an ABC transporter (SiaABC), is the best-described heme capture and import system in GAS. The
function of the remaining siaDEFGH genes is not yet characterized. Mutants in the characterized

heme uptake proteins (shr, shp, or siaABC) exhibit reduced ability to grow on heme iron, but the
partial phenotype indicates other GAS genes contribute to heme metabolism. This dissertation
addresses the knowledge gaps in the current understanding of heme uptake in GAS and
investigates the potential of targeting the surface receptor, Shr, for the development of new
therapy. The first chapter describes a new surface receptor, HupY, and demonstrates that HupY
binds heme in vitro, contributes to iron acquisition from hemoglobin or serum, and GAS
colonization of the mucosal surfaces in mice. The second chapter shows that the siaFGH genes
encode a new type of heme importer that is vital for GAS growth on hemoglobin iron, colonization
of the vaginal surface, and systemic infections in murine models. The third chapter describes highaffinity human monoclonal antibody against the surface receptor Shr, their efficacy in protecting
from GAS infection in murine models, and investigate their defense mechanism. Altogether this
dissertation significantly expands the current understanding of heme metabolism in GAS and lays
the groundwork for the development of new therapeutic measures.

INDEX WORDS: Streptococcus pyogenes, Heme uptake, HupY, SiaFGH, Shr, Protection,
Monoclonal antibody

HEME UPTAKE IN GROUP A STREPTOCOCCUS: A ROLE IN PHYSIOLOGY AND
DISEASE

by

NILANJANA CHATTERJEE

A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
in the College of Arts and Sciences
Georgia State University
2020

Copyright by
Nilanjana Chatterjee
2020

HEME UPTAKE IN GROUP A STREPTOCOCCUS: A ROLE IN PHYSIOLOGY AND
DISEASE

by

NILANJANA CHATTERJEE

Committee Chair:

Zehava Eichenbaum

Committee:

Kuk-Jeong Chin
Roberta Attanasio

Electronic Version Approved:

Office of Graduate Services
College of Arts and Sciences
Georgia State University
May 2020

iv

DEDICATION

This work is dedicated to my beautiful parents,
Gayatry Chatterjee and Kartik Chatterjee,
who have always encouraged me and supported me in all my scholarly pursuits.

“... because all things have contributed to your advancement,
you should include all things in your gratitude.”
― Wallace D. Wattles

vi
ACKNOWLEDGEMENTS

This dissertation would not have been possible without the continued support and love of
several people in my life. First and foremost, I would like to express my deepest appreciation and
sincere gratitude to my dearest supervisor Dr. Zehava Eichenbaum. I could not have completed
this journey without her support, guidance, and inspiration. She has been my mentor, philosopher,
and guide throughout this journey. Thank you, Dr. Eichenbaum, for being the kind and caring
person that you are. Thank you for everything you have done for me.
I would like to extend my sincere gratitude to my committee members, Dr. Kuk-Jeong
Chin and Dr. Roberta Attanasio, for their guidance, continued support, motivation, and
encouragement. I would also like to thank Dr. Parjit Kaur for her support and encouragement. I
am very thankful to Dr. Laura C. C. Cook and her lab for being such an excellent collaborator.
Many thanks to the wonderful staff and core facility of the Biology department. I am especially
indebted to Late Ms. LaTesha Warren for her warmth and continuous assistance. This work would
not have been possible without the financial support from the Department of Biology.
Eichenbaum lab was a friendly and joyful place to work. I want to express my profound
appreciation to all my previous and current lab members who have made my journey comfortable
and memorable. A special thanks to my excellent lab colleagues Edroyal Womack, Fahmina
Akhter, and Kristin Lyles. Thank you for all the moments that we have shared. I would also like
to thank my two undergraduate friends Kieffer Hellmeister and Kolbi Gray. Thank you for all the
fun, laughter, and smiles that we had together. Also, special thanks to Sadia Rahman and Elizabeth
Peterson for being the best lab neighbors.

vii
I would like to express my heartiest thanks to my Atlanta friends and family, who have
always showered me with love and encouragement through this journey. I am especially grateful
to Jami Husain, Sohani Fatehin, Mudabbir Husain, and my Lenox family for their unconditional
love and support. I am deeply indebted to Raiyan Tasnim Hridita and Fahima Aqtar for their help;
otherwise, it would be challenging to continue the journey. I would like to extend my special thanks
and gratitude to Tania Afsana for being the most loving, caring, and supportive big sister.
No words can ever be strong enough to express how grateful I am to my wonderful parents
Gayatry Chatterjee and Kartik Chatterjee. Today what I have achieved, it is only because of your
tireless support, unconditional love, and countless sacrifices. You are the pillar of my strength;
you are the heroes of my success. My baby sister, Suranjana Chatterjee, thank you for being my
powerhouse; thank you for always there for me, listening to me, encouraging me, and supporting
me. The journey became more comfortable with the love, support, and encouragement I have
received from my parents-in-law, Nilima Datta and Biswajit Kumar Datta. A special thanks to
Pallab Kumar Datta, for being the most supportive brother.
My baby, Aradhya, you were my calm in those stressful days. You always welcomed me
with your heavenly smile even when I came home late. Without your support, my angel, working
those long tiring hours in the lab would not be that easy. My sunshine, you made me stronger than
I ever thought I could be. Thank you very much for being the best baby in the world.
Finally, I want to acknowledge the dreamer behind this journey, my amazing husband
Biplab Kumar Datta. It was you who always supported and believed in me even when I did not
believe in myself. Thank you for being the biggest cheerleader for my every success; thank you
for being my steady rock. Without your encouragement, constant reassurance, and love, I would
not be able to finish this journey.

viii
TABLE OF CONTENTS
ACKNOWLEDGEMENTS ....................................................................................................... VI
LIST OF TABLES ................................................................................................................... XIII
LIST OF FIGURES ................................................................................................................. XIV
1

GENERAL INTRODUCTION ........................................................................................ 1
1.1

Group A Streptococcus (GAS) .................................................................................... 1

1.2

Global GAS burden ..................................................................................................... 1

1.3

Leading GAS vaccine candidates................................................................................ 2

1.4

The role of iron in bacterial infections ....................................................................... 3

1.5

Heme uptake mechanisms by bacterial pathogens ................................................... 4

1.6

Heme uptake in GAS ................................................................................................... 5

1.7

Dissertation objectives and significance ..................................................................... 6

2

CHAPTER

I:

TRANSCRIPTOMIC

ANALYSIS

OF

STREPTOCOCCUS

PYOGENES COLONIZING THE VAGINAL MUCOSA IDENTIFIES HUPY, AN
MTSR-REGULATED ADHESIN INVOLVED IN HEME UTILIZATION .............. 7
2.1

Introduction .................................................................................................................. 7

2.2

Materials and methods ................................................................................................ 9

2.2.1

Bacterial strains, media, plasmids, and primers ..................................................... 9

2.2.2

Mouse model of vaginal colonization ...................................................................... 9

2.2.3

RNA collection ........................................................................................................ 10

ix
2.2.4

Detection of eukaryotic and ribosomal RNA from total RNA .............................. 10

2.2.5

Preparation of cDNA libraries for RNASeq .......................................................... 11

2.2.6

RNA sequencing analysis ....................................................................................... 11

2.2.7

Creation of mutant and complemented NZ131 strains ......................................... 12

2.2.8

HupY cloning, purification and heme binding ..................................................... 13

2.2.9

GAS growth in the presence of streptonigrin or using human serum or hemoglobin
as iron source.......................................................................................................... 14

2.2.10 qRT-PCR ................................................................................................................. 15
2.2.11 Ethics statement ...................................................................................................... 15
2.3

Results ......................................................................................................................... 16

2.3.1

Extensive transcriptional remodeling .................................................................... 16

2.3.2

The MtsR regulon of both GAS and GBS ............................................................. 20

2.3.3

HupY protein binds heme in vitro .......................................................................... 22

2.3.4

∆hupY cells have lower intracellular concentrations of iron and impaired ability
to use human serum and hemoglobin as sole iron sources compared to wildtype
(WT) cells ................................................................................................................ 23

2.3.5
2.4
3

HupY plays an important role in vaginal colonization by both GAS and GBS ... 26

Discussion .................................................................................................................... 28
CHAPTER II: A NOVEL HEME TRANSPORTER FROM THE ECF FAMILY IS
VITAL FOR THE GROUP A STREPTOCOCCUS COLONIZATION AND
INFECTIONS.................................................................................................................. 36

x
3.1

Introduction ................................................................................................................ 36

3.2

Materials and methods .............................................................................................. 38

3.2.1

Strains, media, and growth conditions .................................................................. 38

3.2.2

Nucleic acid methods.............................................................................................. 39

3.2.3

Plasmid construction .............................................................................................. 39

3.2.4

Construction of ∆siaFGH mutant and complemented strains ............................. 40

3.2.5

Growth assays for streptonigrin sensitivity and use of hemoglobin iron ............. 40

3.2.6

Iron uptake assays .................................................................................................. 41

3.2.7

Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) analysis .................. 43

3.2.8

Determination of cellular heme content and accumulation ................................. 43

3.2.9

Mouse model of vaginal colonization .................................................................... 44

3.2.10 Mouse model of systemic GAS infection ............................................................... 44
3.2.11 In silico methods ..................................................................................................... 44
3.2.12 Ethics statement ...................................................................................................... 45
3.3

Results ......................................................................................................................... 46

3.3.1

The siaFGH genes encode a putative ECF importer ............................................ 46

3.3.2

Deletion of the siaFGH genes results in higher streptonigrin resistance and
impaired use of hemoglobin iron ........................................................................... 48

3.3.3

The SiaFGH proteins import heme but not iron ion ............................................ 52

3.3.4

SiaFGH contributes to GAS mucosal colonization as well as systemic infection 55

xi
3.4
4

Discussion .................................................................................................................... 57
CHAPTER III: NATIVE HUMAN ANTIBODY TO SHR FROM GROUP A
STREPTOCOCCUS PROTECTS FROM INVASIVE INFECTION ....................... 62

4.1

Introduction ................................................................................................................ 62

4.2

Materials and methods .............................................................................................. 63

4.2.1

Strains and growth conditions ............................................................................... 63

4.2.2

Single B-lymphocyte mAb discovery technology ................................................... 64

4.2.3

Enzyme-linked immunosorbent assays (ELISA)................................................... 65

4.2.3.1 ELISA with Shr proteins ........................................................................................ 65
4.2.3.2 ELISA with synthetic peptides ............................................................................... 65
4.2.3.3 ELISA with immobilized bacteria .......................................................................... 66
4.2.3.4 ELISA with ShrGAS and hemoglobin ..................................................................... 66
4.2.4

GAS growth in hemoglobin and mAb.................................................................... 67

4.2.5

Growth and differentiation of HL60 cells ............................................................. 67

4.2.6

Opsonophagocytosis Killing Assay (OPKA) .......................................................... 67

4.2.7

Passive vaccination and GAS infection model ...................................................... 68

4.2.8

Structural Prediction .............................................................................................. 68

4.2.9

Statistical Analysis .................................................................................................. 69

4.3

Results ......................................................................................................................... 69

4.3.1

TRL96 and TRL186 bind to GAS surface and enhance opsonization ................. 69

xii
4.3.2

TRL186 protects mice from invasive GAS infection ............................................. 70

4.3.3

TRL186 interacts with a short segment in the NTR of Shr .................................. 72

4.3.4

TRL186 interferes with NTR-hemoglobin binding and hemoglobin-dependent
growth of GAS ........................................................................................................ 74

4.3.5
4.4
5

TRL186 interacts with whole-cell and purified Shr of S. dysgalactiae ................ 75

Discussion .................................................................................................................... 76
CONCLUSIONS ............................................................................................................. 81

APPENDICES ............................................................................................................................. 85
Appendix A: Supplemental Tables ....................................................................................... 85
Appendix A.1 (Table S1: Differentially expressed genes (FDR <0.05) between WT NZ131
GAS grown in liquid culture (CDM) to bacteria colonizing the murine vaginal tract
(Mouse)) .................................................................................................................. 85
Appendix A.2 (Table S2: Bacterial strains and plasmids used) ..................................... 105
Appendix A.3 (Table S3: Cloning and qPCR primers) ................................................... 106
Appendix B Supplemental figures ...................................................................................... 108
Appendix B.1 (figure S1: RNA Seq validation)............................................................... 108
Appendix B.2 (figure S2: Expression of hupZ)............................................................... 109
REFERENCES.......................................................................................................................... 110

xiii
LIST OF TABLES
Table 1 Genes repressed by MtsR with differential regulation in the vaginal tract............. 19
Table 2 Lists of strains and plasmids used in this study ......................................................... 42
Table 3 Lists of primers used in this study ............................................................................... 45
Table 4 In silico analysis suggests SiaFGH system is conserved in streptococcal strains .... 48
Table 5 Strains and plasmids used in this study ...................................................................... 64

xiv
LIST OF FIGURES
Figure 1 Differentially expressed genes during GAS growth in vivo ..................................... 18
Figure 2 Differential regulation of MtsR-regulated operons in GAS and GBS and MtsRregulated promoter alignment ....................................................................................... 21
Figure 3 Differential absorption spectroscopy of heme-HupY complex................................ 23
Figure 4 HupY affects intracellular iron concentrations ........................................................ 24
Figure 5 ΔhupY mutants are impaired in growth with serum or hemoglobin as the sole iron
source ............................................................................................................................... 25
Figure 6 ΔhupY mutants in both GAS and GBS are impaired in their ability to colonize the
murine vaginal tract ....................................................................................................... 27
Figure 7 Model of the role of HupY in GAS colonization and heme utilization on mucosal
surfaces............................................................................................................................. 34
Figure 8 The siaFGH genes encode an ECF transporter ........................................................ 47
Figure 9 The SiaFGH importer impacts intracellular iron levels .......................................... 50
Figure 10 The SiaFGH transporter impact the use of hemoglobin iron................................ 51
Figure 11 The SiaFGH transporter promotes heme uptake ................................................... 53
Figure 12 Inactivation of the SiaFGH genes did not influence metal iron uptake ............... 54
Figure 13 Inactivation of siaFGH attenuate GAS vaginal colonization................................. 56

xv
Figure 14 Survival of CD-1 mice from systemic GAS infection ............................................. 57
Figure 15 TRL96 and TRL186 bind to whole-cell and enhance opsonization ...................... 70
Figure 16 TRL186 protects mice from GAS infection ............................................................. 71
Figure 17 TRL186 affinity and binding site ............................................................................. 73
Figure 18 Impact of NTR-hemoglobin binding and hemoglobin-dependent growth in the
presence of TRL186 ........................................................................................................ 75
Figure 19 TRL186 interacts with SDSE cells and Shr protein ............................................... 76

1
1

GENERAL INTRODUCTION

This dissertation focuses on iron and heme metabolism in pathogenic streptococci,
primarily Group A Streptococcus (GAS). The introduction is intended to provide background
information about the pathogen and the area of iron homeostasis.
1.1

Group A Streptococcus (GAS)
Group A streptococcus (GAS), also known as Streptococcus pyogenes, is an obligate

human pathogen and a leading cause of human morbidity and mortality globally. This betahemolytic pathogen presents diverse clinical manifestations. Most frequently, GAS causes mild
infections such as pharyngitis and impetigo, which can resolve upon medical intervention at the
early stage of the disease. On rare occasions, or as a result of delayed treatment, GAS produces
life-threatening invasive infections, such as necrotizing fasciitis and Streptococcal Toxic Shock
Syndrome. Conventional GAS episodes may also lead to severe immune-based sequelae, including
post-streptococcal glomerulonephritis, acute rheumatic fever (ARF), and rheumatic heart disease
(RHD) [1].
1.2

Global GAS burden
GAS produces several million infections worldwide. Based on this heavy burden, the

World Health Organization ranked this pathogen as the ninth leading infectious agent of human
morbidity and mortality. Every year GAS claims approximately 500,000 lives [2]. About 700
million people suffer from non-invasive GAS diseases annually, of which more than 600,000 cases
progress to severe invasive infections with more than160,000 deaths [2]. RHD, which is the most
common cause of non-congenital heart disease in children, alone, is contributing to a substantial
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death toll and chronic disability worldwide, especially in the developing parts of the world. 33.4
million cases of rheumatic heart disease were recorded in 2015, of which 1.2 million cases led to
heart failure [3]. GAS infections are prevalent in low-income countries with low socioeconomic
conditions and overpopulation as major contributing factors [4]. Wealthy nations in the western
hemisphere (e.g., USA, UK, Canada) have been experiencing in the past few years an
unprecedented resurgence in GAS infections. These resurging infections include serious diseases
such as scarlet fever, invasive infections, and puerperal sepsis. England, for example, has suffered
in 2014 from a dramatic escalation in scarlet fever incidences with a case rate increase of more
than 3-fold over one year (8.2 and 27.2 cases per 100,000 in 2013 and 2014 respectively) [5]. The
frequency of invasive GAS infections has recently reached 7-10 cases per 100,000 in the US and
Canada [6, 7]. Notably, the rate of invasive diseases in pregnant and post-partum women is higher
compared to the rest of the population. For example, 109 cases per 100,000 of GAS puerperal
sepsis had occurred in England between 2010-2016 [8]. Penicillin is the recommended antibiotic
to treat uncomplicated GAS infections. However, resistance to drugs (macrolides [9] and
clindamycin [10]) that are used in penicillin-sensitive patients is increasing. Intensive surgical
procedures are required to handle severe invasive infections. Currently, no licensed vaccine is
available against streptococcal diseases. The lack of vaccine along with the rising rate of antibiotic
resistance demands a better understanding of GAS pathogenesis, that may facilitate the design of
novel therapeutics for combating this dangerous human pathogen.
1.3

Leading GAS vaccine candidates
The majority of the vaccine development studies in GAS target the leading virulence factor,

M protein. It is an immunogenic and protective antigen, which elicits long-lasting immunity and
present in a high amount on the GAS surface [11]. However, some serious concerns impede the M
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protein-based vaccine development. Some M proteins (M1 type) induce a dangerous inflammatory
response by triggering the Th1-type cytokine release [12]. Moreover, some of the M epitopes
cross-react with the host antigens and lead to ARF development [13]. Besides, the most exposed
and immunogenic part (amino terminus) of the M protein is hypervariable; there are more than
200 circulating M-based serotypes. Hence, vaccination that targets that hypervariable region often
protects against a limited number of GAS strains [14]. Because of the urgent need, the search for
an M-based vaccine that is safe and broad continues. Two vaccine candidates are currently in
human trials (Phase I). The MJ8VAX vaccine encompasses epitopes for the conserved carboxyl
terminus region of the M-protein [15], and StreptAnova is a 30-valent vaccine that consists of a
mixture of peptides from the hypervariable amino terminus of M protein that represent the most
prevalent serotypes in North America and Europe [16]. Additional vaccine targets consist of
several surface virulence factors. These including the C5a peptidase, Fibronectin-binding protein,
Serum opacity factor, Streptococcal pyrogenic exotoxin, Pili (T antigen), Serine protease
(SpyCEP), and the Metal transporter of streptococcus (MtsA). A recent study from our lab
suggested that the Streptococcal hemoprotein receptor (Shr) is a promising candidate. [17].
1.4

The role of iron in bacterial infections
With only a few exceptions (e.g., Borrelia burgdorferi and some Lactococcal specie),

pathogenic bacteria require iron [18, 19]. Nutritional immunity, which limits the bioavailability of
essential metals such as iron, is a primary defense mechanism used by mammals to protects
themselves against bacterial infection. The vast majority of the iron within the human body is
located intracellularly. Almost 75% of the metal is complexed with the protoporphyrin IX
molecule to form heme, which serves as the prosthetic group of hemoglobin, myoglobin, and other
proteins. Most of the remaining intracellular iron is in ferrihydrite mineral and sequestered within
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the shell of the iron storage protein, ferritin. Hemoglobin and heme that are released into
circulation are rapidly captured and removed by the host carrier proteins, haptoglobin, and
hemopexin. The glycoproteins transferrin (plasma) or lactoferrin (secretion) eliminates free iron
from the extracellular fluids. Altogether, the host withholding of iron results in 10-18 M of the free
metal in the interstitial fluids, an extremely low concentration that is several orders of magnitude
below the 10-6-10-7 M of iron, which most bacteria require to grow [20]. Hence bacteria that invade
the human body deploy high-affinity mechanisms to acquire iron from the host proteins during
infection.
1.5

Heme uptake mechanisms by bacterial pathogens
The largest reservoir of iron in humans is heme. Pathogenic bacteria employ high-affinity

heme scavenging proteins to capture and import heme from circulating host hemoproteins or
protein that are released by hemolysis and tissue damage during infection [21]. The mechanism of
heme uptake is better understood in Gram-negative bacteria. These pathogens often use
hemophores (e.g., Pseudomonas aeruginosa, Yersinia pestis, and Hemophilus influenza, [22-24])
and / or outer membrane receptors (e.g., Neisseria species and Vibrio Cholerae, [25-27]) to remove
heme from host hemoproteins. In both cases, the seized heme is transported through the outer
membrane. In the periplasm, ligand-binding proteins capture the heme and deliver it to a cognate
ABC transporter for translocation through the inner membrane and into the cytosol. The energy
required for the outer membrane transports comes from the proton motive force, via the TonB
ExbB and ExbD system. ATP hydrolysis (by the transporter ATPase) energizes the import across
the inner membrane. Gram-positive bacteria also use hemophores and or heme receptors to capture
heme from the host. Nevertheless, protein relay systems are often used to shuttle the heme through
the thick peptidoglycan of Gram-positive bacteria. Like with Gram-negative organisms, dedicated
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ABC transporters transport the heme into the cytoplasm. [28]. In many Gram-positive bacteria, the
proteins that participate in heme relay across the cell wall use a common protein domain, named
NEAT (NEAr-iron Transporter). The NEAT protein module shares a common fold but exhibits a
significant sequence and functional diversities [29]. The ligands different NEAT domains interact
with include, heme, hemoglobin, and various ECM components [30]. The Isd machinery used by
Staphylococcus aureus is the best described NEAT-based heme acquisition system [28].
1.6

Heme uptake in GAS
GAS utilizes surface receptors that contain NEAT domains to obtain heme and transfer it

through the cell wall. The best-studied heme acquisition pathway in GAS is the Sia system, which
is encoded by a ten-gene operon named sia (streptococcal iron acquisition) [31]. MtsR (metal
transport repressor), a global regulator that controls iron homeostasis in GAS, represses the sia
operon in an iron-dependent manner. [31]. The first five genes of the sia operon, encode Shr
(streptococcal hemoprotein receptor), Shp (streptococcal heme-binding protein), and the ABC
transporter, SiaABC. Shr is a 145 kDa protein with a unique N-terminal region (NTR) followed
by two NEAT domains, separated by a leucine-rich repeat region [29]. Shr binds to hemoglobin
via its NTR that harbors two copies of a unique domain (aka DUF1533). Recently the structure of
one of the Shr DUF1533 domains has been resolved and renamed HID (Hb-interacting domain)
because of its hemoglobin-binding capacity [32]. Following binding to hemoglobin, NEAT1
captures and transfers the heme to NEAT2 or Shp, the second receptor in the pathway. Kinetic
studies suggest that two NEAT domains of Shr are functionally distinct. NEAT1 is involved in
heme uptake and delivery, whereas NEAT2 serves as temporary heme storage. According to the
proposed model, in the presence of a high concentration of heme, holo-NEAT1 rapidly relays heme
to Shp and also delivers heme to apo-NEAT2. In low heme concentration, heme stored in NEAT2
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is transferred back to NEAT1 and then to Shp [33]. A rapid and affinity-driven mechanism is
involved in the transfer of heme from Shp to SiaA [34]. Finally, heme is transported into the
cytoplasm via the SiaBC proteins. The function of the proteins encoded by the remaining genes in
the sia operon is unknown. A second iron-complex transporter has been described in GAS,
SiuADBG/FtsABCD, shown to involve in ferrichrome [35] and heme [36] import. The redundancy
in heme uptake protein highlight the importance of heme iron as a nutrient for GAS.
1.7

Dissertation objectives and significance
The research project aims to expand the current understanding of bacterial heme uptake

mechanisms and to explore if heme uptake proteins could be targeted for the development of new
therapies. Work focused on GAS, a critical human pathogen. This research endeavor facilitated
the discovery of a new surface receptor encoded outside of the sia operon, which is conserved in
GAS and the related group B streptococcus (GBS or S. dysgalactiae). The investigation also
revealed a novel heme transporter, encoded by the sia operon, which is found in other Grampositive pathogens. The role of the new components in heme acquisition in bacterial physiology
and disease process was described. Research efforts also yielded proof of concept for targeting
heme uptake proteins for the development of new modalities for prevention and therapy.
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CHAPTER I: TRANSCRIPTOMIC ANALYSIS OF STREPTOCOCCUS

PYOGENES COLONIZING THE VAGINAL MUCOSA IDENTIFIES HUPY, AN
MTSR-REGULATED ADHESIN INVOLVED IN HEME UTILIZATION
2.1

Introduction
Streptococcus pyogenes (Group A Streptococcus, GAS) is an important primary pathogen

causing severe infections like necrotizing fasciitis and toxic shock syndrome, but it also colonizes
mucosal surfaces, often asymptomatically. Mucosal carriage of GAS in the throat [37-39],
gastrointestinal tract [40], and recto-vaginal tract [41, 42] can serve as principal reservoirs for
community infections. Although the rate of transmission from carriers is lower than in acutely
infected individuals, this reservoir is important on a population level as rates of carriage greatly
eclipse rates of acute infections in the community [43].
Vaginal mucosal colonization by GAS is associated with vulvovaginitis in prepubertal girls
with studies reporting 11-20% of swabs collected from girls with vulvovaginitis contained GAS
[44-46]. A recto-vaginal carrier state has been demonstrated in adult women [42, 47] and although
the level of vaginitis is lower in adults, it has been reported in the literature [40, 48]. A murine
vaginal colonization model has been developed for GAS based on a similar model used for the
related Streptococcus agalactiae (Group B Strep, GBS) [49-51]. Not only does this model allow
for examination of GAS vaginal colonization, but it also provides an easily accessible model for
colonization of host mucosal surfaces. Here, we describe the transcriptome of GAS during murine
vaginal carriage. This work, in conjunction with previous research describing transcriptional
profiles during vaginal colonization by GBS [52], provides an important framework for the genetic
changes streptococcal pathogens undergo during mucosal carriage.
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The environment encountered in mucosal surfaces is vastly different from liquid laboratory
culture, which is reflected in the large number of genetic changes observed via RNASeq. One set
of genes that was highly differentially expressed during GAS vaginal colonization is known to be
under the regulation of MtsR (Spy49_0380c), a master regulator of iron homeostasis and virulence
in GAS and related streptococci [53-55]. In iron-replete conditions, MtsR acts as a negative
regulator of over 40 genes in GAS including the ribonucleotide reductase operon nrdF.2IE.2
operon (spy49_0339-0341) and many genes involved in heme metabolism such as shr
(spy49_1405c), shp (spy49_1404c), siaABC (spy49_1401c-1403c), and hupZ (spy49_0662) [54,
56, 57].
HupZ was recently described as a novel enzyme involved in GAS heme biotransformation.
HupZ binds and degrades heme to generate free iron in vitro [56]. As a cytoplasmic enzyme, HupZ
does not have access to extracellular heme and thus depends on GAS uptake machinery for heme
supply. Heme acquisition in Gram-positive bacteria typically involves surface receptors that
capture heme from the host and deliver it through the peptidoglycan layers to dedicated ABC
transporters in the membrane for import into the cytoplasm [58]. The only receptors for
hemoproteins and heme described in GAS are Shr and Shp, which together consist of a heme relay
system that shuttles heme from the extracellular environment to the SiaABC heme transporter (also
known as HtsABC) [30, 33, 34]. Here we report that the gene adjacent to HupZ, spy49_0661 now
renamed hupY, is highly upregulated during vaginal carriage and is not only important for mucosal
colonization but also plays a role in heme utilization in GAS.
HupY, previously known as LrrG, is a leucine rich repeat protein with homologs in other
species of streptococci, including GBS (SAK_0502). These proteins have previously been
described as LPXTG-anchored cell surface proteins in GAS and GBS that are involved in binding
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epithelial cells. Immunization against LrrG was protective in a mouse model of GAS infection,
and it was also shown to be expressed during a macaque model of acute pharyngitis [59-61].
Genetic location and co-regulation indicate that the function of HupZ and HupY may be related.
We hypothesize that HupY serves as both an adhesin and receptor that facilitates the capture and
uptake of heme into GAS during colonization and infection of the host.
2.2

Materials and methods
2.2.1

Bacterial strains, media, plasmids, and primers

Bacterial strains and plasmids used in this work are listed in Table S2 (Appendix A.2), and
primer sequences are shown in Table S3 (Appendix A.3). BH10C Escherichia coli were grown in
Luria-Bertani medium (LB) and GAS strain NZ131 and its derivatives were grown in Todd-Hewitt
medium supplemented with 2% (w/v) yeast extract (THY) or chemically defined medium [62].
Antibiotics were added at the following concentrations when needed: E. coli chloramphenicol
(Cm), 10 μg ml-1; kanamycin (Kan) 150 µg ml−1, spectinomycin (Spec), 100 μg ml-1; GAS
chloramphenicol (Cm), 3 μg ml-1; kanamycin (Kan) 150 µg ml−1; spectinomycin (Spec), 100 μg
ml-1. Plating of murine lavage fluid was done on CHROMagar StrepB agar plates (DRG,
CHROMagar).
2.2.2

Mouse model of vaginal colonization

Experiments were performed as previously described [50, 63, 64]. Female CD1 mice aged
6-10 weeks were used for all experiments. Briefly, mice were administered an intraperitoneal (IP)
injection of 0.5 mg β-estradiol valerate (Acros Organics) suspended in 100 µL filter-sterilized
sesame oil (Sigma). IP estradiol synchronizes the estrus cycle of the mice. 24 h later, mice were
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inoculated with 107 CFU of bacteria in 10 µL PBS intravaginally using a pipet tip. On days 1, 2,
3, and 5, the vaginal lumen was washed with 50 µL sterile PBS using a pipet tip to flush the liquid
into the vaginal vault 6-8 times. Vaginal lavage fluid was then collected and put on ice for no more
than 30 minutes prior to performing serial dilutions in PBS. Dilutions were plated on CHROMagar
StrepB plates, which allow the growth of GAS with a purple hue.
2.2.3

RNA collection

RNA collection from the murine vaginal tract was done as previously described [52]. 50
µL of vaginal lavage fluid from ten colonized mice for 48 hours was combined (500 µL total) and
put into a tube containing 1 mL Trizol LS Reagent (Ambion) and placed on ice for no more than
30 minutes. Samples were centrifuged at 14,000 x g for 1 minute and the Trizol Reagent was
removed. The Ambion RiboPure Bacteria Kit (Thermo Fisher AM1925) was used to purify total
RNA from the resulting pellets according to the manufacturer protocol. For lysis, the pellets were
resuspended in 250 µL of RNAWiz and mixed with glass beads. The samples underwent 10
minutes of bead beating in a MiniBeadbeater (BioSpec) set to homogenize. DNA was removed
from the total purified RNA using DNaseI treatment for 30 minutes at 37⁰ C. For the preparation
of total RNA from planktonic cultures, bacteria were grown overnight in THY medium. Cultures
were diluted 1:50 in freshly prepared CDM medium and grown to an OD600 of 0.3-0.6. Cultures
were centrifuged at the same OD600 and RNA was prepared and treated with DNaseI as described
above for vaginal lavage without the addition of Trizol LS Reagent.
2.2.4

Detection of eukaryotic and ribosomal RNA from total RNA

Vaginal total RNA samples were depleted of both eukaryotic and ribosomal RNA and
planktonic samples were depleted of only ribosomal RNA as previously described [52]. Eukaryotic
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RNA was depleted using the MICROBEnrich kit (Thermo Fisher AM1901) and ribosomal RNA
was depleted using the MicrobExpress kit (Thermo Fisher AM1905) according to the manufacturer
instructions. Depletion of eukaryotic and ribosomal RNA as well as RNA quality was determined
using a TapeStation 2200 (Aglient) and a Qubit RNA High Sensitivity fluormeter (MBL) by the
DNA Services Facility at the University of Illinois at Chicago Center for Genomic Research. If
analysis showed remaining high quantities of ribosomal RNA, the MicrobExpress kit protocol was
repeated to retreat samples.
2.2.5

Preparation of cDNA libraries for RNASeq

cDNA RNASeq libraries were prepared as previously described [52]. Because of the small
amount of input RNA, cDNA libraries were generated with 10-400 ng of input RNA using the
KAPA Stranded RNA-Seq library (KAPABiosystems, KR0934) according to manufacturer
instructions. Briefly, eukaryotic and ribosomally-depleted RNA samples were fragmented in
fragmentation buffer at 94⁰ C for 6 minutes. Random primers were used to synthesize the first
strand cDNA before second sd synthesis, marking, and the addition of a poly-A tail. Illumina
adapters were ligated to the fragments and the subsequent library was cleaned up using DNA
purifier magnetic beads (101 Bio, P920-30). The library was amplified for 10 cycles followed by
an additional magnetic bead cleanup. Libraries underwent quality control and quantification on the
Tapestation 2200 (Agilent) as above. 20 µL of 50 nM libraries were sequenced and analyzed at
the University of Chicago Genomic Facility with 8 samples multiplexed per RNASeq lane.
2.2.6
The

RNA sequencing analysis
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Streptococcus pyogenes NZ131 genome. Samtools v0.1.19 [30] was used to down-sample all in
vitro mapped samples. Cufflinks v2.2.1 [31] was used to assembly and quantify transcripts to the
NZ131 genome and assemblies were merged using Cuffmerge and wrapped in nCufflinks v2.2.1.
Quantification of transcripts was done using Cuffquant and featureCounts [32]. Differentially
expressed genes (DEGs) with a false discovery rate (FDR) corrected p-value of 0.05 or less and at
least a two fold change were identified using FPKM-based Cuffdiff and count-based edgeR
methods [33].
2.2.7

Creation of mutant and complemented NZ131 strains

NZ131 ΔhupY::aphA3 creation. The NZ131 ΔhupY::aphA3 strain was created as described
previously [52]. Briefly, approximately 1000 bp upstream (primers LC149 Pst / LC150) and
downstream (primers LC151/LC152 NotI) of spy49_0661 (hupY) were amplified by PCR.
Amplification products were fused in a subsequent PCR reaction using outside primers LC149
PstI and LC152 NotI. The fusion product and temperature sensitive pJC159 (CmR) vector were
digested with PstI and NotI restriction enzymes and ligated together. Using inverse PCR, the
plasmid was replicated (primers LC153 MluI / LC154 MluI. The aphA3 kanamycin resistance gene
was amplified from pOSKAR using primers JC292 MluI /JC304 MluI. The resulting linear
fragments were digested with MluI, ligated together and electroporated into competent BH10C E.
coli cells. Colonies were screened on LB plates supplemented with Cm and Kan at a permissive
temperature (30° C). Plasmid was collected and sequenced to ensure correct assembly and then
electroporated into competent NZ131 cells. A temperature-dependent selection process that has
been previously described was used to isolate NZ131 ΔhupY::aphA3 cells [65]. Cells containing
the deletion plasmid were grown at 30° C and then shifted to a higher temperature (37° C) and
plated on Cm/Kan THY plates to select for plasmid integration. Following integration, cells were
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passaged in antibiotic free THY at 30° C twice daily for 4 days to allow for plasmid excision.
Mutants were then selected on THY Kan at 37° C and screened for loss of Cm resistance. Colonies
that grew at 30° C in Kan but not Cm were sequenced to confirm the proper genotype. pLC007
complementation plasmid. The complementation plasmid pLC007 was created by amplifying the
hupY gene from NZ131 genomic DNA using primers LC184 / LC185. Plasmid pJC303, which
contains a constitutive recA promoter digested using NotI and BamHI. The digested plasmid and
amplified hupY genes were combined in a Gibson assembly reaction using 2x NEBuilder Hifi
DNA Assembly mix. The assemble plasmid, pLC007, was electroporated into BH10C E. coli cells
and plated on LB plates containing spectinomycin. Plasmid was purified, sequenced, and
electroporated in competent NZ131 ΔhupY::aphA3 cells and the resulting cells were plated and
propagated on THY Kan, Spec plates.
2.2.8

HupY cloning, purification and heme binding

The construction of HupY-His expression vectors was accomplished by TOPO® directional
cloning according to the manufacturer instruction (Invitrogen, K101-01). The hupY gene was
amplified from GAS NZ131 chromosome using the ZE435/ZE436 primer set (Table S3, Appendix
A.3) and introduced into the pET101/D-TOPO vector (Table S2, Appendix A.2). The resulting
plasmid, pZZ1, codes for a HupY-His tag fusion protein expressed from the T7 RNA polymerase
promoter. The recombinant HupY protein was produced and purified from E. coli as previously
described [56]. Briefly, cells were harvested and resuspended in 20 mM Tris-Cl, 100 mM NaCl,
0.1% Triton X-100, pH 8.0, with the addition of 0.5 mg/mL lysozyme and protease inhibitor
(Complete mini-EDTA-free, Roche), and lysed by sonication. The cell debris was removed by
centrifugation and the cleared lysate was applied to a HisTrap HP affinity column (GE Healthcare)
and purified using a FPLC. Heme titration and differential spectroscopy of HupY-heme complex
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was conducted as described [30]. In short, haemin chloride (in DMSO) was added in increasing
concentrations to 17 µM apo-HupY (in PBS), the solution was allowed to incubate at room
temperature for five minutes prior to UV-visible scan. PBS with equal amounts of heme served as
the blank. The differential UV–visible absorption spectrum was acquired at room temperature by
UV-Vis spectrophotometer (Beckman Coulter, DU730).
2.2.9

GAS growth in the presence of streptonigrin or using human serum or

hemoglobin as iron source
Sterptonigrin killing assays: Streptonigrin stock solutions (Sigma, 2mg/ml) were prepared
in chloroform and methanol at 1:1 (v/v) and kept in -20° C up to six months. In each experiment,
overnight GAS cultures grown in THYB were used to inoculate fresh broth (OD600 of 0.01)
containing streptonigrin in various concentrations. The culture optical density was determined
after 20 hours incubation at 37° C. Serum and hemoglobin use assays: New 1M Dipyridyl (2,2’
Dipyridyl, Acros Organics) prepared in absolute ethanol and 1mM human hemoglobin (Sigma)
prepared in saline (and filter sterilized) were used in all experiments. Fresh THYB containing 3
mM Dipyridyl and increasing amounts of pooled normal human serum (Innovative Research) or
human hemoglobin were inoculated with overnight GAS cultures grown in THYB (OD600 of 0.01).
The culture optical density was determined after 20 hours incubation at 37° C. In all experiments,
bacteria were grown statically in 6 ml broth in 15 ml screw cap Falcon tubes. The WT and ΔhupY
strains were grown in THYB without antibiotics as the strains were observed to be stable without
selection in antibiotics (unpublished data and Table S2). The complemented strain
(ΔhupY/pLC007) was cultivated with spectinomycin (100 µg /ml) during the first overnight
growth. The presences of the antibiotic markers (kanamycin for ΔhupY and spectinomycin for the
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complementation plasmid) was confirmed by viable counts using the appropriate antibiotics at the
end of each experiment.
2.2.10 qRT-PCR
Quantitative reverse transcriptase PCR was done to validate RNASeq data and test the
polarity of the ΔhupY GAS and GBS mutants on the downstream hupZ gene. qPCR primers are
listed in Table S3, Appendix A.3. RNA was collected and treated with DNaseI as above. cDNA
was then prepared using the iScript cDNA synthesis kit (Bio-Rad) according to manufacturer’s
instructions. cDNA was amplified using random hexamers and diluted 1:5 prior to qPCR. For
GAS, the proS (primer pair LC082/LC083) gene and for GBS, gyrA (primer pair LC060/061),
were used as housekeeping reference genes. Amplification was done using iTaq Universal SYBR
Green Supermix or SSoAdvanced Universal SYBR Green Supermix (Bio-Rad) in a CFX96 Real
Time Detection System (Bio-Rad). Samples were run in triplicate technical replicates and at least
duplicate biological replicates.
2.2.11 Ethics statement
All mouse experimentation was approved by the University of Illinois at Chicago Animal
Care and Use Committee (ACC) and IACUC under protocol #16-068. All animal work was carried
out using accepted veterinary standards in accordance with the Animal Care Policies of the
University of Illinois at Chicago Office of Animal Care and Institutional Biosafety Committee and
IACUC. This institution has Animal Welfare Assurance Number A3460.01 on file with the Office
of Laboratory Animal Welfare, NIH.
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2.3

Results
2.3.1

Extensive transcriptional remodeling

Mice were vaginally inoculated with GAS strain NZ131 and, after 48 hours of colonization,
vaginal lavage samples containing GAS cells were collected for RNASeq analysis. Vaginal
carriage samples were compared to log-phase NZ131 bacteria grown statically at 37 ⁰C in
chemically defined laboratory medium (CDM). Of the 1686 NZ131 genes with transcripts
detected, 581 genes, were differentially expressed with a False Discovery Rate (FDR) corrected p
value of ≤ 0.05. Of those, 491 genes had a fold change of ≥2-fold (Table S1, Appendix A.1) and
Figure 1). To validate RNASeq findings, qualitative Real-Time PCR was done on two genes
shown to be downregulated in the vaginal tract (Figure S1, Appendix B.1).
Like the previously published transcriptome of GBS in the murine vaginal tract [52], there
are extensive changes in metabolic pathways associated with host colonization in GAS. Similar to
GBS, GAS cells significantly down-regulated the fatty acid biosynthesis fab operon
(spy49_1359c-1371c), ostensibly resulting in increased long-chain fatty acids. In other species of
streptococci including Streptococcus gordonii and S. salivarius, an increase in long-chain and
mono-unsaturated fatty acids was observed in response to acidic pH and hypothesized to be an
adaptive response to acidic environments [66] (Table S1, Appendix A.1) and [52]).
Both GAS and GBS also highly upregulated homologous phosphotransferase systems
essential for the import of a variety of sugars such as ascorbate (spy49_0154-1055 and sak_1833183), mannose (spy49_0834-0836 and sak_1908-1910), maltose (spy49_1028-1030 and
sak_1475-1477), and galactose and fructose (spy49_1327c-1329c and sak_1893-1895). Genes and
operons involved in degradation of sugars such as ascorbate (spy49_0156-0158, 0160 and
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sak_1820, 1830-1832), galactose (spy49_0673, 1322c-1323c, 1325, 1326c and sak_0345-346,
1878-1890), and malate (spy49_0864, 0865c and sak_1651 and 1878) were often also upregulated
in both organisms (Table S1, Appendix A.1) and [52]).
Not all homologous metabolic pathways were similarly regulated between GAS and GBS.
During GBS colonization, genes involved in the de novo purine biosynthetic pathway
purCLFMNH (sak_0057, sak_0059-0061, sak_0063) and purDEKB (sak_0076-0078 and
sak_0080) were upregulated between 2 and 25 fold [52]. Interestingly, the purine biosynthesis
pathway in GAS (spy49_0020-0025, spy49_0027-0029, and spy49_31) was significantly downregulated during colonization compared with log-phase growth in the same medium (Table S1,
Appendix A.1). Although GAS and GBS are closely related species that both colonize mucosal
surfaces, their metabolic profiles, while similar, demonstrate some distinct transcriptional changes
associated with vaginal colonization. Growth phase is an important factor determining
transcriptional profiles. Growth in the vaginal tract does not equate to log phase growth in liquid
culture, which likely explains some of the observed large-scale transcriptional shifts. Some genes
highly upregulated during stationary phase in liquid culture are also upregulated in the vaginal
tract. speB and mf for example, are known to be upregulated during stationary phase liquid growth
and expressed at lower levels during other phases of growth [67]. In the vaginal tract compared
to log-phase growth, speB and mf expression are highly upregulated (Table S1, Appendix A.1).
In contrast, there are also genes like clpE, that have previously been shown to be upregulated
during stationary phase compared to log phase growth [68] but are down-regulated during growth
in the vaginal tract compared to liquid growth (Table S1, Appendix A.1). This indicates that cells
colonizing mucosal surfaces cannot be characterized by typical liquid growth phases. This was
previously observed for mucosal colonization in GBS as well, where colonization of the vaginal
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tract showed some genetic signatures of stationary phase growth but some characteristics of
different phases of liquid growth [52].

Figure 1 Differentially expressed genes during GAS growth in vivo
Volcano plot showing transcriptomic changes in GAS genes during growth in liquid versus
colonizing the murine vaginal tract with – Log10 False Discovery Rate (FDR) adjusted p value on
the y axis and Log2 fold change during murine vaginal growth on the x axis. Genes in blue were
significantly differentially expressed with an FDR adjusted p value of < 0.05 and a fold change of
>2. Genes known to be regulated by the metal regulator MtsR are shown in red and hupY
(spy49_0661)/hupZ (spy49_0662) are specifically marked.
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Table 1 Genes repressed by MtsR with differential regulation in the vaginal tract
Gene

Name

Description

spy49_0247
spy49_0339
spy49_0340

pbp7
nrdF.2
nrdI

spy49_0341
spy49_0381

nrdE.2
mtsA

spy49_0382
spy49_0383
spy49_0661
spy49_0662
spy49_1159c

mtsB
mtsC
hupY
hupZ
manB

spy49_1374c
spy49_1395c
spy49_1396c
spy49_1397c
spy49_1398c
spy49_1400c
spy49_1401c
spy49_1402c
spy49_1403c/
1404cc

dnaK
siaH
siaG
siaF
siaE
siaD
siaC
siaB
siaA/shp

spy49 _1405c
spy49_1687c

shr
prsA

D-Alanyl–D-alanine carboxypeptidase
Ribonucleotide reductase
Ribonucleotide reductase stimulatory
protein
Ribonucleotide diphosphate reductase
Metal ABC transporter, substrate
binding
Metal ABC transporter, ATP binding
Metal ABC transporter, permease
Adhesion and heme receptor
Enzyme, heme degradation
Phosphoglucomutase,
phosphomannomutase
Chaperone protein
ECF transporter, A component
ECF transporter, T component
ECF transporter, S component
Putative ABC transporter
Putative ABC transporter
Heme ABC transporter, ATP binding
Heme ABC transporter, permease
Heme ABC transporter, substrate
binding/streptococcal heme-associated
protein
Streptococcal hemoprotein receptor
Foldase

a

Fold upregulation in the vaginal tract compared to liquid growth.

b

False discovery rate-corrected P value.

c

Fold
changea
2.4
432.03
1079.15

P valueb

245.77
6.23

1.80E 29
1.10E 19

1.83
2.24
27.26
37.69
13.35

0.00791
0.0007
1.10E 21
8.40E 17
3.20E 19

3.05
2.56
2.7
4.71
7.03
12.49
15.68
10.82
20.58

0.01803
0.00283
0.00464
2.70E 08
4.10E 10
6.10E 09
4.90E 07
1.90E 07
3.80E 08

25.46
144.61

4.10E 12
7.43E 17

0.00565
3.60E 27
6.20E 20

Annotation of NZ131 incorrectly lists spy49_1403c (siaA) and spy49_1404c (shp) as a single
fused gene product rather than two distinct genes.
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2.3.2

The MtsR regulon of both GAS and GBS

Notably, some of the most highly upregulated genes during vaginal carriage include those
previously shown to be directly regulated by MtsR. MtsR regulates genes involved in iron and
heme metabolism and this regulation is dependent on the concentration of iron and manganese.
The MtsR regulon includes the metal transporter mtsABC (spy49_1554-1556) and the 10 gene
streptococcal iron acquisition locus (sia), which includes shr (spy49_1405c), shp (spy49_1404c),
and siaA-siaH (spy49_1395c-1398c, 1400-1403c) [53, 69], all of which are significantly
upregulated between 2.5 and >25 fold during growth in the vaginal tract (Table 1 and Figure 1).
Annotation of NZ131 incorrectly lists siaA and shp as a single fused gene product, although they
are actually separate genes [57]. Because of the annotation error, gene upregulation for shp and
siaA were measured together over the course of the single transcript, which was highly
upregulated. Because the genes are separate but coregulated, the upregulation of shp is inferred
from RNASeq data.
In addition, MtsR has been shown previously to directly repress genes such as the
nrdF.2IE.2 operon (spy49_0339-0341), which is upregulated over 200-fold during vaginal
colonization (Table 1 and Table S1) but does not regulate the related nrdHEF genes which are
slightly repressed in the vaginal tract [54]. In total, at least 20 genes, about half of those previously
shown to be repressed by MtsR, were significantly upregulated in our RNASeq data (Table 1).
Mining previously published transcriptomic data shows that GBS homologs of genes in the
GAS MtsR regulon including mstABC (sak_1554-1556) and nrdF.2IE.2 (sak_499-501), were
similarly upregulated during vaginal colonization and contain putative MtsR promoter DNA
binding sites (Figure 2B and [52]). Consensus promoter sequences match previously published

21
known MtsR binding sites [54]. It is likely that the MtsR regulon in GBS is similar to GAS and
previous transcriptomic data [52] as well as this study suggest that the regulon is de-repressed
during streptococcal host colonization (Table 1 and Figure 1).
Transcription of MtsR-regulated spy49_0662, also known as hupZ, as well as the gene
immediately upstream, spy49_0661, are both increased during vaginal colonization (Figure 1,
Figure 2A, and Table 1). Previous RNASeq data from GBS strain A909 colonizing the vaginal
tract also showed significant upregulation of the homologous hupYZ gene pair [52] and a putative
MtsR binding site is located upstream of spy49_0661 in both organisms (Figure 2B). In addition,
the MtsR-regulated nrdF.2IE.2 operon is located adjacent to the homologous gene pair in GBS
(Figure 2A).

Figure 2 Differential regulation of MtsR-regulated operons in GAS and GBS and MtsRregulated promoter alignment
(A) Select MtsR-regulated operons of GAS and GBS are shown. Red genes are hupYZ homologs
and blue genes are nrdF.2I.2E.2 homologs. Fold change during in vivo growth is shown in white.
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Values from GBS A909 were previously reported [52]. (B) Promoter alignment of select MtsRregulated genes in both GAS and GBS.
2.3.3

HupY protein binds heme in vitro

spy49_0661 had previously been designated lrrG in GBS [59] because of its leucine rich
repeat region. GAS and GBS LrrG homologs have been demonstrated to be important adhesins
that play a role in infection [59, 60]. HupZ can degrade heme and thus may free iron from heme
inside the GAS cell [56] but, as it is a cytoplasmic protein, it does not have the ability to import
heme on its own. To begin testing if Spy49_0661 contributes to heme metabolism in GAS, we
cloned and purified the protein. HupY did not exhibit significant absorption other than at 280 nm
(Figure 3, 0 µM heme) indicating it was purified from E. coli in the apo form. In vitro heme
binding was tested by titration of the apo protein with increasing amounts of free heme. A growing
absorbance band with maximum at 414 nm appeared in the resultant solution with incremental
addition of heme (Figure 3). The absorption maximum at the Soret region (390–430 nm)
demonstrated by HupY following incubation with heme is characteristic of protein-bound heme
and is distinguishable from that of free heme in solution [56]. Plotting the differential absorbance
at the Soret peak as a function of heme concentration (Figure 3) indicated that heme-binding was
dose dependent, saturable and with a stoichiometry of 3:1 (protein to heme) indicating that
Spy49_0661 can bind heme in vitro. We designate this gene hupY (heme utilization protein Y)
based on its proximity to hupZ and its role in heme utilization.
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Figure 3 Differential absorption spectroscopy of heme-HupY complex
An increase of heme bound to HupY (17 µM) as increasing concentrations of heme were added to
the protein is shown by the sharp peak at 414 nm. The insert displays the changes in absorbance
at 414 nm plotted against heme concentration. The data are representative of at least two
independent spectroscopic analyses, 0 µM line at axis.
2.3.4

∆hupY cells have lower intracellular concentrations of iron and impaired

ability to use human serum and hemoglobin as sole iron sources compared to
wildtype (WT) cells
To test the role of HupY in iron metabolism in vivo, a deletion of hupY was created in GAS
strain NZ131. Strains were tested for their ability to resist killing by streptonigrin, an antibacterial
whose potency depends on the levels of intracellular iron [53, 70]. The hupY mutant was able to
grow to an OD600 of 1.0 in the presence of high levels (3.5 µM) streptonigrin. At these
concentrations, little to no growth was observed in WT NZ131. The addition of hupY on a plasmid
under a constitutive promoter was able to partially restore the killing phenotype seen in WT cells
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(Figure 4). This indicates that the ΔhupY mutant strain has lower intracellular iron concentrations
than the WT strain when grown in THYB.

Figure 4 HupY affects intracellular iron concentrations
Growth (20 h) of an NZ131 wildtype (blue), ΔhupY mutant (red) and complemented
(ΔhupY/pLC007, gray) strains in THYB or in THYB containing streptonigrin. The data are from
two independent experiments done in technical triplicates with standard deviation shown. The
asterisk indicates significance (p <0.05, Student’s t-test, equal variance).
To test if HupY contributes to the use of heme iron by GAS, THYB medium was treated
with dipyridyl, a liposoluble iron chelator. Human serum or hemoglobin were then added to the
medium and the ability of GAS strains to grow in these media was tested. Addition of human
serum restored the growth of WT NZ131 in the dipyridyl-containing THYB. This ability was
significantly decreased in the ΔhupY mutant strain and could be complemented (Figure 5A). This
indicates that the ΔhupY strain is impaired in its ability to obtain iron from human serum. Similarly,
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human hemoglobin was able to support the growth of WT GAS while the ΔhupY mutant had a
severe growth defect when growing in hemoglobin as the sole iron source (Figure 5B).

Figure 5 ΔhupY mutants are impaired in growth with serum or hemoglobin as the sole iron
source
Growth (20 h) of an NZ131 wildtype (blue), ΔhupY mutant (red) and complemented
(ΔhupY/pLC007, gray) strains in THYB, THYB with dipyridyl (DP), or THYB-DP supplemented
with human serum (5-20 % final volume, (A) or human hemoglobin (B). The data are from two
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independent experiments done in technical triplicates with standard deviation shown. The asterisk
indicates significance (p <0.05, Student’s t-test, equal variance).
2.3.5

HupY plays an important role in vaginal colonization by both GAS and

GBS
HupY homologs were previously suggested to serve as adhesins with important roles in
binding to epithelial cells [59]. We hypothesized that HupY would be important for mucosal
colonization of the murine vaginal tract. To test this, mice were inoculated with WT NZ131, an
isogenic ΔhupY mutant and a mutant strain containing pLC007, a plasmid containing a copy of
NZ131 hupY under the control of a constitutive promoter. Initial inoculation and day 1 colonization
levels were not statistically different between these strains. By day 2 of colonization, the mutant
strains were impaired in colonization and by days 3 and 5, the mutant strains colonized the mice
at significantly lower levels than the WT or complemented strains (Figure 6A).
Because the hupY homolog in GBS is closely related and also upregulated in the vaginal
tract [52], we hypothesized that this gene would also play a role in colonization of the vaginal tract
by GBS. Like GAS, a GBS ΔhupY mutant is impaired in colonization of the vaginal tract. The
mutant strain was able to be complemented, at least partially, using the GAS hupY gene (pLC007),
indicating that the heme binding and/or attachment phenotype is likely conserved between GAS
and GBS (Figure 6B).
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Figure 6 ΔhupY mutants in both GAS and GBS are impaired in their ability to colonize the
murine vaginal tract
WT and isogenic ΔhupY mutants in GAS (A) or GBS (B) were used to colonize the murine vaginal
tract. In both cases, the GAS hupY gene was used to complement the mutant strains. Both
NZ131ΔhupY and A909ΔhupY mutants were attenuated for vaginal colonization compared to WT
GAS and GBS and both mutants were able to be at least partially complemented by the addition
of GAS hupY on a plasmid. Statistical significance was assessed using a one-way ANOVA and
non-parametric Kruskal Wallis test; the asterisk indicates significance (p <0.05), n.s. not
significant.
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2.4

Discussion
Bacteria must alter transcriptional programs to survive and adapt to changing

environments. In this study, we analyzed the transcriptome of GAS colonizing the murine vaginal
tract. These data provide a new and important look at the genetic regulation of various metabolic
and virulence pathways in GAS during mucosal carriage. With over one quarter of the genome
differentially expressed during mucosal carriage compared to liquid culture, clearly transcriptional
remodeling during colonization is extensive.
Comparing the GAS vaginal transcriptome to the recently published GBS vaginal
transcriptome offers much insight into the similarities and differences in the way these two related
organisms adapt to a mucosal environment. While many genes and pathways involved in metabolic
processes were similarly regulated in GAS and GBS there were also many pathways such as purine
biosynthesis, that were upregulated in one species and down regulated in the other (Table S1
(Appendix A.1) and [52]). These two species obviously share many similarities in terms of
adapting to the vaginal environment, but some distinct transcriptional differences are also
observed. Comparing transcriptomic profiles from organisms collected from the same model
system provides important insight into the differing colonization rates and infections caused by
these organisms at the vaginal mucosa.
One striking observation from this data is that many genes in the MtsR regulon are highly
activated during GAS colonization of the murine vaginal tract (Table 1). MtsR, an important
regulator of metal homeostasis, mediates repression of metal acquisition genes in GAS including
genes involved in heme utilization and iron and manganese transport. Although GBS also contains
an MtsR homolog, much less is known about MtsR regulation in GBS. Examining the previously

29
published vaginal transcriptome, homologous genes with potential MtsR binding sites are also derepressed during GBS colonization (Figure 2 and [52]).
MtsR was first described as a DtxR family regulator repressing expression of the
streptococcal iron acquisition (sia) operon in the presence of high levels iron and manganese [53].
It was later shown that MtsR controls the expression of 64 genes in GAS including many that
impact iron and heme metabolism. MtsR mutants have been shown to be attenuated for virulence
in zebrafish infection models [53] and MtsR has also been shown to affect transcription of
important GAS virulence factors including mga, emm49, and ska via direct binding to promoter
regions [54].
Iron is an essential nutrient and heme is a major source of iron for organisms growing in
the human host. To use heme as an iron source, bacteria must be able to bind, transport, and utilize
the iron present in heme. In GAS, the surface receptor Shr is important for iron uptake as it binds
to heme-containing proteins like hemoglobin and myoglobin, sequesters the heme and transfers it
to another surface receptor, Shp

and then to the SiaABC ABC transporter system for

internalization (Figure 7 and [30, 53, 71-73]). Both Shr and Shp contain NEAT (near iron
transporter) heme binding domains found in heme binding proteins of other Gram-positive bacteria
such as the iron-regulated surface determinant (Isd) proteins of Staphylococcus aureus [58]. In
Shr, NEAT1 and NEAT2 are separated by a leucine rich repeat domain [30]. shr, shp, and the
siaA-H genes are all present in a single operon controlled by MtsR and all were found to be derepressed during colonization of the vaginal tract by GAS.
In iron-complete medium, shr is expressed more highly during log phase growth in liquid
culture and expression is decreased during stationary phase, (Eichenbaum, unpublished results).
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Starving the cells for iron, however, increases further shr transcription during log phase due to
MtsR depression [54]. In our data, shr expression is higher on the mucosal surface than during log
phase growth in liquid culture, consistent with iron limitation conditions in the mucosal surfaces.
Thus, it is likely that the observed up-regulation of these genes is associated with iron availability
in the mucosa rather than the difference in growth phase of the two conditions being compared by
RNASeq.
spy49_0661, here renamed hupY, and the gene immediately downstream of it, hupZ, are
also negatively regulated by MtsR in GAS and a putative MtsR binding site is found upstream of
hupYZ in both GAS and GBS (Figure 2B and [54]). hupYZ are both significantly upregulated
during vaginal colonization by both GAS and GBS (Figure 2 and [52]). HupZ was recently
described as a novel GAS enzyme that binds heme and is involved in heme biotransformation in
vitro. Interestingly, HupZ which belongs to a group of atypical heme degrading enzymes, does
bind and degrade heme although it is missing key residues found in this protein family [56, 74].
As a small cytoplasmic enzyme, HupZ does not appear able to transport heme into the cell and
would thus rely on other heme binding and transport proteins. Although complementation indicates
that the observed phenotypes can be attributed to HupY, because hupYZ appear to be under the
control of a single promoter, we tested whether the allelic exchange of hupY with aphA3 (KanR)
affected expression of hupZ. qRT-PCR data showed no significant change in the expression of
hupZ between the WT GAS or GBS and the ΔhupY strains (Figure S2).
HupY (Spy49_0661 in NZ131 GAS and SAK_0502 in A909 GBS), previously referred to
in the literature as LrrG, was initially identified as a leucine rich repeat protein and putative surface
adhesin. The protein sequences of the Spy49_0661 and SAK_0502 homologs in GAS strain
NZ131 and GBS strain A909 are 72% identical and both contain an LPXTG motif and surface
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localization has been observed in both GAS [60] and GBS [59, 75] homologs. Both have 15 22amino acid leucine rich repeat regions matching the consensus sequence for bacterial leucine rich
repeat proteins (LRRs) [59, 76]. The proteins are related to the internalins InlA and InlB from
Listeria monocytogenes, which are important for bacterial adhesion to host surfaces via the Ecadherin receptor and subsequent invasion into host cells [77-79]. Because of their similarity to
internalins and because LRRs are generally involved in protein-protein interactions, previous
studies on the LrrG homologs focused mainly on their adherence properties.
SAK_0502 has been shown to bind to fixed HEp-2 lung epithelial cells and ME180 cervical
epithelial cells although with a stronger preference for cervical cells over lung cells [59].
Subsequent studies demonstrated binding to the human scavenger receptor gp340 by both GAS
and GBS HupY homologs [80]. gp340 is expressed by immune cells and epithelial cells including
genital tract cell lines such as VK2E6E7 vaginal epithelial cells and HEC1A endometrial
carcinoma cells and has been shown to be important for HIV transmission in the genital epithelium
[81]. Based on this data, it is likely that HupY serves an adhesive function in the vaginal tract.
HupY homologs have also been proposed as potential vaccine candidates as they are highly
conserved and surface-expressed proteins [59, 60, 80]. Immunization against the HupY homologs
protected against lethal challenge with GAS, GBS, and Streptococcus equi ssp. epidemicus species
[59, 60, 82].
Adhesins have been known to have alternative functions as in the case of the GBS protein
Lmb that is involved in both adherence to human laminin [83] and invasion into brain endothelial
cells [84] as well as zinc uptake [85]. Similarly, Shr enhances GAS attachment to laminin in
addition to its function in heme uptake [86]. Based on the genetic relationship with hupZ and direct
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repression by MtsR, we hypothesized that HupY may have a dual role in adherence and heme
uptake and degradation as well.
Data presented here show that HupY is able to bind heme in vitro (Figure 3), providing
evidence that it may serve as a heme receptor that helps transfer heme inside the cell to HupZ for
degradation. In addition, NZ131ΔhupY cells are killed less efficiently by streptonigrin, an
antibacterial compound that is preferentially toxic to cells with higher levels of intracellular iron,
indicating that NZ131ΔhupY cells have less intracellular iron than WT and complemented strains
(Figure 4). This provides evidence that HupY may not only bind heme but may also play a role in
transporting it into the cell for use as a bacterial iron source. GAS cells were also tested for their
ability to grow using hemoglobin or serum as a sole iron source. ΔhupY mutants had impaired
growth under these conditions, indicating that HupY contributes to the ability of GAS to obtain
heme iron from serum and hemoglobin.
Because hupY was highly upregulated in the vaginal tract and because of its observed
properties as an adhesin, we tested the ability of GAS and GBS ΔhupY mutants to colonize the
murine vaginal tract. Both GAS and GBS ΔhupY mutants were significantly impaired in their
ability to colonize the vaginal tract. Complementing the mutation using the GAS hupY homolog
restored the colonization phenotype in both GAS and GBS, indicating similar functions in both
organisms (Figure 6). Although it appears that HupY is necessary for vaginal colonization, some
questions remain to be answered. We have not yet elucidated whether decreased colonization
levels are due to decreased adherence to mucosal surfaces or decreased survival due to inability to
acquire iron from the host. In addition, this mucosal colonization has only been tested in the vaginal
tract and remains to be examined at other mucosal sites streptococci are known to colonize such
as the nasopharynx. In GBS the HupY homolog, SAK_0502, was found to bind preferentially to
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cervical cell lines over lung cell lines [59]. It is possible that its role as an adhesin is host mucosal
site-specific, while its role in heme binding and utilization is more universal. Further experiments
to determine the potential interplay between the adhesion and iron homeostasis functions of HupY
are currently underway.
Unlike heme receptor proteins like Shr and Shp that contain recognized NEAT domains,
HupY does not contain any known heme binding domains. Leucine rich repeat domains are found
in both HupY and Shr and could play a role in heme binding by a novel unknown mechanism. A
full analysis of the protein structure and domains involved in binding both the host and heme is an
important next step and will allow determination of whether these binding sites are localized to
the same regions of the protein.
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Figure 7 Model of the role of HupY in GAS colonization and heme utilization on mucosal
surfaces
In the presence of high levels of iron, iron-bound MtsR represses a large number of genes including
the sia operon which includes the genes for the siaABC heme importer as well as shr, and shp
heme binding proteins. In addition, MtsR represses the manganese and iron mtsABC transporter,
hupZ and hupY. MtsR also downregulates the mtsABC gene cluster in a manganese dependent
manner ([69], not shown in the model). In iron deplete conditions such as on mucosal surfaces,
MtsR repression is relieved, leading to upregulation of these operons. Shr captures heme (from
host hemoproteins or the environment) and delivers it to Shp and subsequently to the SiaABC for
import into the cell. Once inside the cell, iron can be liberated from heme by the HupZ enzyme.
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HupY, coregulated with HupZ, is a surface protein that has the ability to bind heme. We propose
that HupY binds heme to allow transport to HupZ, either through the Shp/SiaABC heme import
pathway or another mechanism. Open arrows indicate possible heme transfer pathways. HupY also
plays a role in mucosal colonization, possibly as an adhesin important for binding to host cells.
It also remains to be tested whether HupY plays a role in iron acquisition and utilization in
GBS as well as GAS although all evidence would point to this. The presence of an MtsR binding
site upstream of GBS hupYZ, the genetic neighborhood of the genes (Figure 2), and the fact that
GAS hupY can complement the in vivo mutant phenotype in GBS (Figure 6) strongly indicate that
these genes have similar functions in GAS and GBS.
Here we have identified a gene, hupY, previously thought to encode an adhesin in GAS and
GBS, which serves additional functions important for GAS colonization including heme binding.
Both hupY and hupZ as well as other members of the MtsR regulon are highly de-repressed during
in vivo mucosal colonization in both GAS and GBS. Likely in conjunction with its co-regulated
neighboring gene, hupZ, HupY acts as a heme binding protein involved in regulating intracellular
iron levels.
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CHAPTER II: A NOVEL HEME TRANSPORTER FROM THE ECF FAMILY IS
VITAL FOR THE GROUP A STREPTOCOCCUS COLONIZATION AND
INFECTIONS

3.1

Introduction
Group A Streptococcus (GAS) is a significant pathogen and a leading cause of human

morbidity and mortality. The Gram-positive GAS is the etiological agent of common infections
such as pharyngitis and impetigo. These simple episodes can lead to immune-based complications
in susceptible individuals with severe outcomes, such as acute rheumatic fever, rheumatic heart
disease (RHD), and post-streptococcal glomerulonephritis. GAS also produces rare but lifethreatening conditions, including bacteremia, necrotizing fasciitis, and Streptococcal Toxic Shock
Syndrome [1, 87]. Altogether, GAS is responsible for several million cases globally and claims
approximately 500,000 lives annually [2]. RHD and invasive infections are the primary culprits in
GAS related mortality [3, 7]. The development of a vaccine against GAS has met serious
challenges due to hypervariability and cross-reactions with host epitopes. Hence, the control of
GAS infections continues to rely on conventional antibiotics. Still, resistance to macrolides and
clindamycin, which are used as an alternative [9] or together with β-lactams [10], is on the rise.
The establishment of infection requires pathogens such as GAS to successfully compete
with the host for iron [88, 89]. GAS cannot obtain iron from the host ferric proteins, transferrin, or
lactoferrin [89]. But, this β-hemolytic pathogen thrives on heme iron, and can readily remove heme
from hemoglobin and other host hemoproteins [89]. The best-characterized heme uptake system
in GAS is encoded by the 10-gene Sia operon [72]. The Sia mechanism consists of two surface
proteins, Shr and Shp, and the heme ABC transporter, SiaABC. The remaining siaDEFGH genes
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are yet to be described. Shr binds to hemoglobin on the surface, extracts the heme, and delivers it
through the cell wall to Shp, using a shared heme-binding module named NEAT [30, 33]. A rapid
and affinity-driven mechanism then mediates the transfer of heme from Shp to SiaA, the substratebinding component of the SiaABC transporter, for import into the cytoplasm [34, 90, 91]. Shr, the
first protein in the Sia heme-relay system, is important for virulence [57, 86] and serves as a
protective antigen in both passive and active vaccination models [92]. The bicistronic operon,
hupYZ, also contributes to GAS growth on heme iron. HupY is a cell-wall receptor that binds heme
in vitro [93]. A hupY deletion mutant is impaired in the use of serum or hemoglobin as a source of
iron and exhibits lower iron content when cultivated in vitro. The mechanism by which HupY
captures heme from the surface and delivers it into the cytoplasm remains unknown. HupZ is a
cytoplasmic enzyme that binds and degrades heme in vitro [56, 74]. The sia and the hupYZ operons
are both negatively regulated by iron availability via the metal responsive regulator, MtsR [94].
Besides SiaABC, the only other iron-complex transporter reported in GAS is the
SiuADBG/FtsABCD system. The SiuADBG/FtsABCD proteins consist of an ABC transporter
that was implicated in the uptake of ferrichrome [35] as well as heme [36] and thus may exhibit
broad specificity for iron compounds. In summary, three surface proteins and two conventional
ABC transporters function in heme capture and import in GAS. This redundancy highlights the
essentials nutritional role heme iron plays in GAS.
The energy-coupling factor (ECF) transporter family, is an unusual type of ABC importers
that is widespread among Gram-positive bacteria [95]. ECF transporters are comprised of a small
membrane-embedded protein that provides substrate specificity (S component/EcfS) and an ECF
module consisting of a transmembrane protein (T component/EcfT), and a pair of similar or
identical cytosolic ATPases (A component/EcfA) [96, 97]. The suggested import mechanism by
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these non-canonical ABC transporters involves the toppling and repositioning of the S protein to
facilitate substrate capture at the extracellular side and its release into the cytoplasm [95]. Hence,
the S component is the only ECF component suggested to interact with the ligand. Twenty-seven
different S families have been identified, each for a separate micronutrient (e.g., various vitamins,
amino acids, queuosine, or trace metals, not including iron or iron complexes) [96, 98]. The ECF
family is categorized into two groups. In Group I, a single S-component interacts with a specific
ECF module, whereas, in the Group II system, multiple S components of unrelated sequence and
various ligands, can form a complex with the same ECF module [95, 96]. Some S components,
referred to as Solitary, do not have a recognized ECF module [99]. The genetic organization
suggests that GAS siaFGH genes code for a Group I ECF system, in which all of the components
are co-expressed and work exclusively together. The siaFGH genes are expressed in response to
iron deprivation as part of the sia operon and along with the rest of the MtsR regulon. We
hypothesize that siaFGH genes encode a novel heme import system that is imperative for the
establishment of GAS infection.
3.2

Materials and methods
3.2.1

Strains, media, and growth conditions

The strains and plasmids used in this study are listed in Table 2, and primers are listed in
Table 3. Escherichia coli (E. coli) were used for cloning and grown aerobically in Luria-Bertani
(LB) medium at 37° C with shaking. GAS cells were grown statically at 37 °C in Todd-Hewitt
broth (THY, Difco Laboratories) with 0.2% w/v yeast extract (THYB) or Chemically Defined
Medium (CDM; SAFC Biosciences) [36]. When necessary, 100 μg/mL ampicillin, 100 μg/mL
spectinomycin, 70 or 300 μg/mL kanamycin (for E. coli and GAS, respectively), or 500 μg/mL
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erythromycin was added to the medium. All of the constructed chromosomal mutations are stable.
Hence, antibiotics were used for strain construction and only when the strains were recovered from
glycerol stocks.
3.2.2

Nucleic acid methods

We used the PureLink Genomic DNA Mini Kit (Invitrogen) to extract chromosomal DNA
and the Wizard Plus Minipreps DNA Purification System (Promega) for plasmid DNA. DNA was
amplified by PCR using the AccuTaqTM LA DNA Polymerase (Sigma). DNA fragments were
purified from agarose with the S.N.A.P. UV-free gel purification kit (Invitrogen). T4 DNA ligase
(Roche) was used for ligation reactions. Restriction enzymes and DNA modifying enzymes were
purchased from NEB and used according to the manufacturer’s recommendations. Transformation
and all molecular and genetic manipulations were performed according to the manufacturer’s
instructions and standard protocols [100, 101].
3.2.3

Plasmid construction

The plasmids and strains used in this study are described in Table 2 and the primers in
Table 3. Plasmid pHNG7: A DNA fragment with the siaFGH genes and ~ 1Kb flanking region
was amplified from NZ131 chromosome, with the primers ZE480/ZE481, and fused to pCR-XLTOPO using the TOPO TA Cloning kit (Invitrogen) [102]. Plasmid pHNG10: A DNA fragment
generated by inverse PCR from pHNG7 was cut with NheI and ligated to a PCR fragment encoding
aad9 gene (spectinomycin resistance), amplified from pJRS525 with the primers ZE408/ZE409
and digested with NheI. Plasmid pHNG12: A DNA fragment with the ∆siaFGH::aad9 allele was
amplified from pHNG10 with primers ZE451/ZE452, cut with ClaI, and ligated into pJRS700 [31,
36] linearized with ClaI. Plasmid pNC111: The siaFGH genes were amplified from NZ131
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chromosome using the primers ZE836/ZE837 digested with PstI, and ligated into pMSP3535 [103]
cut with PstI.
3.2.4

Construction of ∆siaFGH mutant and complemented strains

GAS mutants were constructed by homologous recombination using a temperature
sensitive shuttle vector and establish protocols. ZE4950 (∆siaFGH::aad9 in NZ131): Mutant
construction involved the following steps: 1) Introduction and propagation of pHNG12 in NZ131
under the permissive conditions (i.e., growth at 30 C with spectinomycin); 2) Selection for GAS
clones with a chromosomally integrated pHNG12 on kanamycin at 37 C; and 3) A screen for
clones with a second homologous recombination using passages in broth at 30 C followed by
plating on kanamycin at 37 C. Mutants were identified by replica plating. The mutation in clones
with the kanamycin sensitive and spectinomycin resistance phenotype were confirmed by PCR
analysis. The complemented ZE4952 strain was created by transforming pNC111 into ZE4950
background. ZE151 (∆siaFGH::aad9 in MGAS5005) and ZE152 (wildtype rescue): Plasmid
pHNG12 was introduced into MGAS5005 and the mutant was selected as described for ZE4950.
To isolate the wild type rescue strain, GAS was plated at 37 C without antibiotics following the
passages at 30 C (Step 3 above), and cells that are sensitive to both kanamycin and spectinomycin
were identified by replica plating. The genotypes of the mutant and the wildtype rescue strains
were confirmed by PCR analysis.
3.2.5

Growth assays for streptonigrin sensitivity and use of hemoglobin iron

Streptonigrin sensitivity: Streptonigrin (Sigma) stock solutions (2 mg/mL) were prepared
in chloroform and methanol at 1:1 (v/v) and stored at -20° C. In each experiment, fresh THYB
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containing 0 - 5µM streptonigrin was inoculated with overnight cultures (starting OD600 = 0.01).
The culture optical density was determined following 20 h incubation at 37°C. GAS use of
hemoglobin iron: New 1 M 2,2’ dipyridyl (DP, Acros Organics) stock solution prepared in
absolute ethanol and 1 mM human hemoglobin (Sigma) prepared in saline (and filter sterilized)
were used in all experiments. In each experiment, fresh THYB containing 3mM DP and
hemoglobin (0 - 20 µM) were inoculated with overnight GAS cultures (starting OD600 = 0.01). The
culture optical density was determined following 20 h incubation at 37°C.
3.2.6

Iron uptake assays

Iron uptake assays were performed as previously described with small modification [36].
Fresh CDM prepared without iron (and thus contains only trace iron levels) was inoculated with
GAS cells and the culture was allowed to grow to the mid-exponential phase (~35 Klett units) at
37 C. 1.3 μM
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FeCl3 (Perkin Elmer, specific activity: 18.55 mCi/mg, concentration: 38.80

mCi/mL) prepared in 1 mM sodium ascorbate (ferrous uptake) or 0.0075 M HCl (ferric uptake)
was added to 1.4 mL culture. Samples (200 μL) were drawn every 30 minutes and washed twice
with 500 μL of CDM with 2 mM DP. Radioactivity (counts per minute, c.p.m) was measured for
5 minutes using a 3H standard with a Beckman LS6500 scintillation counter. The sample optical
density was also determined using a Beckman DU730 UV/Vis Spectrophotometer.
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Fe

incorporation was standardized by cell quantity by dividing c.p.m in the cell pellet by the culture
OD600.
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Table 2 Lists of strains and plasmids used in this study
Strain name

Characteristics

References

M49 serotype
NZ131 derivative with the ∆siaFGH::aad9 mutation
ZE4950 with pNC111 expressing the siaFGH genes
ZE4950 with pMSP3535 (empty vector)
M1 serotype
MGAS5005 derivative the ∆siaFGH::aad9 mutation
Wildtype rescue of MGAS151

Lab stock
This study
This study
This study
Lab stock
This study
This study

S. pyogenes
NZ131
ZE4950
ZE4952/pNC111
ZE4952/pMSP3535
MGAS5005
MGAS151
MGAS152
E. coli
JM109
DH5α

TOPO 10

endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB+ Δ(lac- Lab stock
proAB) e14- [F' traD36 proAB+ lacIq lacZΔM15]
hsdR17(rK-mK+)
F– endA1 glnV44 thi 1 recA1 relA1 gyrA96 deoR
Lab stock
nupG purB20 φ80dlacZΔM15Δ(lacZYA-argF)U169,
hsdR17(rK–mK+), λ–
endA1recA1F- mcrA Δ(mrr-hsdRMS-mcrBC)
Invitrogen
Φ80lacZΔM15 Δ lacX74 araD139 galU galK
Δ(araleu)7697 rpsL (StrR) nupG

Plasmids

pNC111
pJRS525

TOPO Cloning vector, KanR
pCR-XL TOPO derivative with the siaFGH region, KanR
pHNG12 derivative with the ∆siaFGH::aad9 allele, KanR
pAMβ1 (from pIL252), ColE1 replicon, ErmR, nisRK,
PnisA
pMSP3535 with the siaFGH gens under PnisA
Broad host-range vector, SpecR

pJRS700

pVE6037 derivative, KanR, TmS

pCR-XL TOPO
pHNG7
pHNG12
pMSP3535

Invitrogen
This study
This study
[103]
This study
Lab stock
[104]
Lab stock
[105]
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3.2.7

Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) analysis

Fresh THYB containing 0.5 µg/mL Nisin and 80 µM FeCl3 (Fisher Scientific) were
inoculated with GAS from overnight culture (starting OD600 = 0.01) and incubated at 37°C for 20
h. Culture samples (5mL, OD600 = 0.8) were washed three times with phosphate-buffered saline
(PBS) prior to collection. Cell pellet was digested and analyzed (Center for Applied Isotope
Studies, University of Georgia, Athens, GA) as described [106, 107].
3.2.8

Determination of cellular heme content and accumulation

Fresh THYB containing 20 µM of hemoglobin with or without 0.5 µg/mL nisin was
inoculated with overnight GAS cultures (initial OD600 =0.01) and incubated at 37°C for 20 h.
Culture samples (standardized according to cell density) were collected, washed 5x with PBS,
resuspended in 2 mL of DMSO and subjected to sonication (20 % amplitude for 30 s.). Cellular
heme amount was determined using acidified chloroform extraction as described [108, 109].
Briefly, 2 mL of 50 mM glycine buffer (pH 2.0), 0.1 mL of 4 N HCl (pH 2.0), 0.2 mL of 5 M NaCl
(pH 2.0) and 2mL chloroform were added to the experimental samples and standard heme solutions
and mixed vigorously by vortex. The reactions were incubated at room temperature for 1 min prior
to centrifugation (20,000 x g, 20 min at 4 °C). The absorbance of the organic phase at 388, 450
and 330 nm was fed into the correction equation Ac= 2 ×A388 − (A450+A330). Heme content
was estimated from the plot of Ac corrected for standard heme concentrations. Heme accumulation
assays: cells were grown in THYB and 20 µM of hemoglobin. Nisin (0.5 µg/mL) was added to
the culture at the early logarithmic phase (20-30 Klett units), to induce the siaFGH expression.
Samples (standardized according to cell density) were collected at the 0, 1, 2 and 3 h time points
and cellular heme content was determined as described above.
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3.2.9

Mouse model of vaginal colonization

Eight-to-ten-week old female outbred CD-1 mice were acclimated and randomly
distributed into experimental groups. Experiments were performed as described [64, 93, 110-112].
Briefly, mice were estrus-synchronized by an intraperitoneal administration of 0.5 mg of βestradiol valerate (Acros Organics) suspended in 100 µL of filter-sterilized sesame oil (Sigma) 24
hours prior to inoculation. NZ131 and ZE4950 strains were grown to OD600 of 0.3-0.5 in THYB
and concentrated to 109 CFU/mL in PBS. Mice were intravaginally inoculated with 107 CFU of
GAS culture in 10 µL of PBS. On days 1, 2, 3, and 5 post-inoculation, the vaginal lumen was
gently washed with 50 µL PBS. The bacteria in the resulting vaginal lavage were enumerated by
viable counts using StrepB selective plates (CHROMagar).
3.2.10 Mouse model of systemic GAS infection
CD-1 female mice (weight, 20–22 g, Charles River Laboratories) were acclimated and
randomly distributed into experimental groups. Culture of ZE151 (∆siaFGH::aad9 in MGAS5005)
and ZE152 (wildtype rescue) grown in THYB were harvested at the mid-logarithmic phase
(O.D.600 = 0.7), washed, and resuspended in saline. Mice were infected intraperitoneally with 0.1
mL of cell suspension at 1.4 x 108 CFU. The animals were observed 4 times per day after challenge,
and mice exhibiting signs of severe distress were euthanized and counted as dead.
3.2.11 In silico methods
SiaF

ribbon

structure

was

predicted

using

I-TASSER

(https://zhanglab.ccmb.med.umich.edu/I-TASSER/) [113] and visualized using molecular
visualization software Pymol. FASTA sequence of each protein was retrieved from the NCBI
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database and then analyzed in the BLASTP server (https://blast.ncbi.nlm.nih.gov/) for the
comparative analysis.
3.2.12 Ethics statement
All mouse experimentation was conducted according to the approved protocol by the
Institutional Animal Care and Use Committee of Georgia State University and Binghamton
University.
Table 3 Lists of primers used in this study
Primers
Name

Sequence (5'-3')

Restriction
site

ZE389

CCTATTTGTACAGCAATATTGTCTGCAGG

NheI

ZE393
ZE408
(spec)
ZE409
(spec)
ZE451

AAAACTGCAGGCGCTTGCTTATACTCTG
TTTGCTAGCGGTCGATTTTCGTTCGTGAATACATG

NheI

GGGAAATCGATACAGCAATATTGTCTGCAGG

ClaI

ZE452

CAAATGCGCATCGATTTCAAAAGCTG

ClaI

ZE480
(siaFGH)
ZE481
(siaFGH)
ZE691
(siaF)
ZE692
(siaF)
ZE836
(siaFGH)
ZE837
(siaFGH)
SpecFw

ATGATAACAGGCGCATTTGC

SpecRev

GTCCATTCAATATTCTCTCCAAGATAACTA

GGGGCTAGCCGAAAGTCTATGCAAGGGTTTATTG

CACTACTTAGAAGTTCTTCATCATGTG
CACCAAACAGTTAACAATAAAAGATATT
TCATGATAACAATCCTGATT
AAAGGATCC TTCCCTAAAAGAGGTG

BamHI

CCCTGCAG CTATTATACAAGAGTTCC

PstI

GTGAGGAGGATATATTTGAATACATACGAA
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3.3

Results
3.3.1

The siaFGH genes encode a putative ECF importer

In silico analysis suggested that the SiaFGH proteins consist of the Group I ECF family of
transporters [95], with siaFGH respectively encoding the substrate-binding S component (EcfS),
the transmembrane T component (EcfT), and the energy-coupling A component (EcfA, Figure
8A). Based on the substrate-binding component, SiaF, the SiaFGH transporter belongs to the
HtsTUV ECF subgroup, whose ligands are unknown [96]. SiaF is predicted to be an α only protein
with both the N and C terminals in the cytosol (data not shown) [114]. Six distinct helices make
up the transmembrane domains, and an extended extracellular loop connects two of the helices in
SiaF [115]. The predicted SiaF ribbon-structure (Figure 8B) is highly similar to the overall fold
and membrane topology shared by EcfS units with one exception; the large extracellular loop that
typically connects helices 1 and 2 in EcfS proteins, joins helices 5 and 6 in SiaF. This difference
is intriguing since this loop is proposed to serve as a lid over the binding site. The SiaFGH proteins
are highly conserved in GAS isolates and the related S. dysgalactiae and S. equi, both of which
encode the entire sia operon. (Table 4).
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Figure 8 The siaFGH genes encode an ECF transporter
A. Schematic representation of the SiaFGH ECF transporter. SiaFGH proteins belong respectively
to the subgroups 3.A.1.31.1; 3.A.1.25.4; and 3.A.1.25.6, in the transporter classification (TC)
database (http://www.tcdb.org) [116]. The red oval indicates the substrate. B. SiaF structural
model (I-TASSER [113]) based on Bacillus subtilis EcfS (PDB#5delA).

48
Table 4 In silico analysis suggests SiaFGH system is conserved in streptococcal strains
Percent identity to GAS SiaFGH proteins
SiaF
(ACI61675)

SiaG
(ACI61674)

SiaH
(WP_136048563.1)

S. dysgalactiae

86.80%
(WP_129556215.1)

66.37%
(WP_111717518.1)

85.66%
(WP_143928109.1)

S. equi

75%
(WP_043040123.1)

64.6%
(WP_165626339.1)

77.42%
(WP_043026841.1)

S. canis

86.80%
(WP_003045124.1)

74.34%
(WP_164227913.1)

85.66%
(WP_164405649.1)

S. castoreus

79.19%
(WP_027969907.1)

68.37%
(WP_027969908.1)

79.21%
(WP_027969709.1)

S. phocae

73.10%
(WP_054278834.1)

65.74%
(WP_054278835.1)

78.85%
(WP_037595860.1)

S. ictaluri

74.62%
(WP_008086912.1)

59.11%
(WP_008087003.1)

78.06%
(WP_008087568.1)

NCBI accession number is in parenthesis

3.3.2

Deletion of the siaFGH genes results in higher streptonigrin resistance

and impaired use of hemoglobin iron
Expression of Group I ECFs is often regulated according to ligand requirement; hence, the
repression of the siaFGH genes by iron and heme [31, 94] suggests that the SiaFGH substrate is
related to iron metabolism. To test this hypothesis, we constructed a deletion mutant in M49
NZ131 background and examined the impact on GAS physiology. The parental NZ131 and the
isogenic ∆siaFGH (ZE4950) grew equally well in THYB (Figure 9), but the mutant was more
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resistant to the antibiotic streptonigrin (LD50 > 3.5 μM for ZE4950 and 3 μM for NZ131). Iron
potentiates bacterial killing by streptonigrin [70]. Hence, increased resistance suggests the
∆siaFGH strain has lower levels of cellular iron compared with the parental NZ131. We next tested
if the function of the siaFGH genes is related to heme uptake, similarly to that of the neighboring,
shr, shp, and siaABC genes. We examined the wildtype and the mutant strains when cultivated in
iron-depleted medium (THYB with DP) supplemented with hemoglobin. Deletion of the siaFGH
genes impaired growth on low concentrations of hemoglobin (2.5 - 10 µM, Figure 10A). But the
addition of hemoglobin at higher levels resulted in similar growth by both strains. These data
support the hypothesis that SiaFGH is a high-affinity heme importer, and consistent with the
redundancy of heme uptake mechanisms in GAS. The siaFG genes are integral membrane
proteins, and thus are difficult to clone under a constitutive promoter. Thus for complementation
analysis, we cloned siaFGH under the nisin dependent promoter, PnisA [89]. Inducing siaFGH
expression with nisin improved the ability of the mutant harboring the complementation plasmid
to grow on hemoglobin iron compared with the mutant carrying an empty vector (Figure 10B).
Therefore, siaFGH expression in trans complements the defect in the use of hemoglobin as an iron
source. Complementation is partial, however, and is observed only with 10 μM hemoglobin and
above.
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Figure 9 The SiaFGH importer impacts intracellular iron levels
Growth (20 h) of NZ131 (wildtype) and ZE4950 (∆siaFGH) in THYB with increasing
concentrations of streptonigrin at 37 °C. The data are from two independent experiments done in
technical triplicates, with SD shown. * indicate significance (P ˂ 0.05, Student’s t test, equal
variance).
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Figure 10 The SiaFGH transporter impact the use of hemoglobin iron
Shown is growth (20 h) of NZ131 (wildtype) and ZE4950 (∆siaFGH), (A) or
ZE5950/pNC111(complement) and ZE4950/ pMSP3535 (empty vector), (B). Cells were grown in
THYB with 3 mM DP with or in THYB-DP with hemoglobin. Data are derived from three
experiments done in triplicates. * indicate significance (Student’s t test, P ˂ 0.05).
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3.3.3

The SiaFGH proteins import heme but not iron ion

To investigate if the SiaFGH system takes up heme, we studied heme accumulation in the
mutant and complemented pair. GAS was grown overnight in THYB and 20 µM hemoglobin with
or without nisin. The cellular heme levels in culture samples of equal cell density were determined
as previously described [108, 109]. The complemented strain accumulated 90% more heme in
response to nisin, and about twice as much compared with the mutant (Figure 11A). Therefore,
the induction of the siaFGH gene expression results in increased heme import. The complemented
strain accumulated more heme even in the absence of nisin, indicating some basal level of PnisA
activity. To study heme uptake over time, we grew cells in THYB with hemoglobin and added
nisin to the culture at the early logarithmic phase. Heme content in samples collected at 0, 1, 2,
and 3 hours after induction was determined (Figure 11B). While we observed a slow increase in
heme levels over time in the mutant strain (harboring an empty vector), the addition of nisin to the
complemented strain resulted in a much faster heme uptake. Together, these observations establish
that the SiaFGH promotes heme uptake in GAS.
To test if SiaFGH imports iron ions in addition to heme, we monitored radioactivity
accumulations in cells grown in iron-deplete CDM supplemented with 55Fe in the ferrous (Figure
12A) or the ferric (Figure 12B) form. Interestingly, both strains incorporated radioactivity at a
faster rate when supplied with reduced iron compared to the oxidized form. The deletion of the
siaFGH genes, however, did not affect import of the metal in either state significantly. We also
compared iron accumulation between in a ∆siaFGH strain carrying an empty vector, and a mutant
harboring the complementation plasmid. The mutant and complemented pair were grown in THYB
supplemented with 80 µM iron and nisin, and we determined the iron content in cell samples
collected after overnight growth using ICP-MS (Figure 12C). Similar amounts of iron were found
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in both strains, indicating that the induction of the siaFGH genes did not result in enhanced uptake
of the metal iron.

Figure 11 The SiaFGH transporter promotes heme uptake
A. Cultures of ZE4950 (∆siaFGH) harboring plasmid pNC111(complement) or pMSP3535
(empty vector) were grown overnight in THYB supplemented with 20 µM hemoglobin with or
without nisin. Cells were harvested, washed, and were subjected to chloroform extraction. UV-
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visible spectra (250–700 nm) of the collected organic phases were recorded and the concentrations
of heme in the test samples were calculated as described [108]. B. The same as in A, only that
nisin was added to the cultures at the early exponential phase, and the heme content was
determined in samples collected at 0, 1, 2, and 3 h post nisin addition.

Figure 12 Inactivation of the SiaFGH genes did not influence metal iron uptake
Shown is the uptake of ferrous iron (A) or ferric iron (B) by NZ131 (wildtype) and ZE4950
(∆siaFGH) grown in iron-deplete CDM supplemented with
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Fe. The data is derived from two

experiments done in duplicates; SD is shown (error bars). Total iron content in ZE151 (wildtype)
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and ZE152 (complemented) strains grown overnight in THYB supplemented with 80 µM FeCl3
and nisin, as determined ICP-MS (C). The data are derived from two independent experiments.
3.3.4

SiaFGH contributes to GAS mucosal colonization as well as systemic

infection
We recently observed that the entire sia operon is induced during vaginal colonization in
mice [93]. We, therefore, used this infection model to test the role of the SiaFGH transporter in
GAS colonization of the mucosa (Figure 13). Estrus-synchronized mice were inoculated
intravaginally with the M49 NZ131 (wildtype) or ZE4950 (∆siaFGH) strain, and the colonization
rate was followed for five days. Although there was an obvious trend of higher colonization in the
mice inoculated with the wildtype strain immediately, we observed no statistical significance
between the wildtype and the mutant strain in the first day of the experiments. A significant
colonization defect, however, was exhibited by the siaFGH mutant on the second day.
Colonization remained much lower than that of the wild type strain through the third day, but it
was lost on day 5 for both the wild type and the mutant strain. To test if the SiaFGH system also
impacts GAS invasive disease, a ∆siaFGH mutant (ZE151) and a wildtype rescue strain (ZE152)
were constructed in the virulent M1 MGAS5005 background and examine in a murine model for
systemic infection (Figure 14). Mice were infected intraperitoneally, and survival was recorded
for five days. Infection by the wild type strain (ZE151) caused a rapid and lethal infection
(resulting in a 20% survival rate in day 2). Mice infected with the mutant strain, however, exhibited
a slower disease with a lower mortality rate (50% final survival rate). Together, data shows that
the siaFGH genes are imperative for mucosal colonization as well as systemic infection.
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Figure 13 Inactivation of siaFGH attenuate GAS vaginal colonization
NZ131 (Wildtype) and ZE4950 (ΔsiaFGH) were inoculated into the vaginal vault of mice, and
colonization rates were determined. Significance was assessed on daily samples using a Mann
Whitney test. * p value < 0.05, ** p value < 0.005.
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Figure 14 Survival of CD-1 mice from systemic GAS infection
Kaplan-Meier survival curve is shown for mice following intraperitoneal infection (1.4 x 108 CFU)
with ZE150 (wildtype rescue, solid line) or ZE152 (∆siaFGH (dash line). The data are pooled from
two independent experiments (log-rank test, P < 0.05, n = 30).
3.4

Discussion
The 10 gene sia operon belongs to the core genome in GAS, S. dysgalactiae, and S. equi,

which are chief human and animal pathogens. We and others have elucidated the structure/function
of shr, shp, and siaABC, and established their role in heme acquisition, adherence, and virulence
in multiple serotypes [30, 33, 34, 57, 72, 86, 90-92, 117-119]. However, the sia operon has five
additional genes (siaDEFGH) that are yet to be described. The data in this study show that the last
three genes, siaFGH, encode a novel ECF transporter that imports heme and promotes GAS
colonization and infection. Notably, heme uptake in bacteria was described so far only with
conventional ABC transporters. In GAS, the two typical ABC systems that import heme are
SiaABC and the SiuADBG (which may also take up ferrichrome). This is the first heme ECF

58
system to be described. Hence the finding of a new heme transporter in the sia operon from the
ECF system family, expands the paradigm of heme uptake not only in GAS but also in the related
S. dysgalactiae and S. equi and in bacteria overall.
SiaFGH belongs to one of the few ECF families whose ligand was unknown [96].
Inactivation of the siaFGH resulted in decreased sensitivity to streptonigrin (Figure 9).
Streptonigrin binding to metal iron leads to structural changes that facilitate a transition from a
partially active form into a fully functioning state [120, 121]. Therefore, the difference in
streptonigrin susceptibility suggests the ∆siaFGH mutant accumulates lower levels of total iron
when cultivated in normal THYB. THYB is a beef heart infusion supplemented with the iron/heme
rich yeast extract and contains both metal iron and heme. The observed changes in iron levels in
the siaFGH mutant grown in THYB could therefore result from a reduction in uptake of either free
iron or heme. Growth experiments, however, suggested that the siaFGH imports heme, since the
mutant did not grow as well as the wildtype in iron-deplete THYB (THYB-DP) supplemented with
hemoglobin (≤ 10 μM, Figure 10A). Expressing siaFGH in trans complemented the mutant
phenotype (Figure 10B). The observation that the mutant phenotype was lost when the cells grew
with 20 μM hemoglobin implies that, like other ECF systems, the SiaFGH is a high-affinity
importer whose role becomes redundant in the presence of a higher amount of hemoglobin. This
redundancy is likely due to the activity of additional transporters, such as SiaABC and SiuADBG.
We used direct heme import assays to test the suggestion that heme serves as a ligand for
the SiaFGH proteins (Figure 11). The expression in trans of the siaFGH genes (from PnisA) resulted
in heme accumulation by the complemented strain when grown overnight with hemoglobin
(Figure 11A). Furthermore, the activation of siaFGH genes in exponentially growing cells (in
THYB with hemoglobin) triggered a pronounced heme uptake in cells harboring the
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complementation plasmid (Figure 11B). The noticeable amount of heme that was present in the
siaFGH mutant, even in the absence of the complementation plasmid, likely resulted from the
activity of other heme transporters. We also noted some basal activity of PnisA. Together the data
identify the siaFGH as a heme importer.
To examine if the SiaFGH system also imports metal iron, we conducted iron uptake and
accumulation assays using 55Fe (Figure 12). We did not observe any impact on the import of ferric
or ferrous iron in the deletion mutant (Figure 12A & B). Also, the induction of the siaFGH genes
did not promote more iron intake in the cells grown on THYB supplemented with ferric iron.
Hence the SiaFGH importer is specific for heme. We noted, however, that both the wildtype and
the mutant cells import ferrous iron more readily compared to the oxidized ferric state. As acidforming bacteria, GAS might create a reduced microenvironment during growth, and its import
systems might be better adapted for the uptake of reduced iron.
Inactivation of the siaFGH impaired GAS growth on hemoglobin as the sole source of iron
(Figure 10) and the pathogen’s ability to import heme from hemoglobin (Figure 11). Hemoglobin
is too large to diffuse through the cell wall and reach the membrane SiaFGH transporter. Grampositive pathogens typically use surface receptors to capture heme from hemoglobin or other host
sources on the bacterial surface and shuttle it through the cell wall to a membrane transporter [28,
72]. In GAS, Shr, Shp, and SiaABC together create such a heme relay system [30, 33, 34, 72, 90,
91]. It seems possible that SiaF also interacts with one or more of the heme relay components
encode by the sia operon. SiaF may receive the heme also from the recently described heme
receptor, HupY [93]. Alternatively, small amounts of heme that are released by hemoglobin
arrived at the membrane and reach SiaF. Additional studies are required to examine these
possibilities and to describe the mechanism of heme capture by the SiaFGH transporter.
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GAS is not able to obtain the iron it needs for growth from the ferric glycoproteins,
lactoferrin, or transferrin [36, 89]. To survive and cause infection, the beta-hemolytic pathogen
metabolizes the heme it sequesters from hemoglobin and other host hemoproteins. Examination of
the siaFGH mutant in a murine model for mucosal colonization revealed the transporter is critical
for GAS establishment in the vaginal track in mice; the mutant colonized only one mouse (out of
nine) comparing to the 8 animals that were colonized by the wildtype strain (day 3 P < 0.005,
Figure 13). The strong activation of the MtsR regulon in this infection model [93], suggests the
transporter plays a key role in GAS adaptation to the vaginal mucosa, and indicates that highly
restricted iron availability confronts bacteria attempting to colonize this niche. Notably, the
siaFGH mutant is also attenuated in a murine model for systemic GAS infection (Figure 14). The
attenuation of virulence by the mutant strain is less dramatic compared to the mutation impact in
the model for colonization. This tempered reduction in virulence implies that iron availability
might be less limiting during systemic growth (compared to the mucosal surfaces).
This study identifies the SiaFGH system as a novel transporter that imports heme in high
affinity, and a new virulence factor in GAS. Homologs of this new heme transporter are found in
the chromosome of additional bacteria. For example, in addition to GAS, the related S.
dysgalactiae and S. equi, harbor the entire sia operon (including the siaFGH genes). We also
identified homologs of siaFGH next to siaDE-like genes in Streptococcus gordoni and Eggerthella
lenta or near iron-dependent repressors in the Group B streptococcus and Enterococcus faecalis.
Finally, while this manuscript was under preparation, a study describing a heme ECF system from
L. lactis was published in the Preprint service for Biology (Verplaetse E et al., not peer reviewed).
In silico analysis also suggest that ECF- type transporters mediate siderophore import. Zoe Heather
et al., described a novel non-ribosomal peptide synthetase (NRPS) system in S. equi that produce
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the siderophore, equibactin [122]. The eqbHIJ genes in this gene cluster, which are predicted to
import iron-equbactin complex, also belongs to the ECF family (NCBI-Protein ID: EqbH/EcfS
CAW93973, EqbI/EcfT: CAW93972, EqbJ/EcfA CAW93970). Therefore, transporters from the
new ECF family may import other types of iron-complexes in addition to heme.
In summary, multiple bacteria, including dangerous pathogens, carry a SiaFGH-type heme
transporter. Hence, describing the mechanism of this new import system and its role in bacterial
pathophysiology may facilitate future methods for prevention and treatment with broad
applicability.
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CHAPTER III: NATIVE HUMAN ANTIBODY TO SHR FROM GROUP A
STREPTOCOCCUS PROTECTS FROM INVASIVE INFECTION

4.1

Introduction
The bacterial pathogen GAS is the ninth leading infectious source of human morbidity and

mortality, with a global burden estimated to exceed 500,000 deaths annually [123, 124]. GAS
commonly colonizes the mucosal surfaces and skin, frequently causing pharyngitis and impetigo.
These infections can lead to severe immune sequelae, such as acute rheumatic fever and
glomerulonephritis [123]. Timely treatment with antibiotics can mitigate GAS infections and their
complications, but resistance to penicillin alternatives are on the rise [9, 10, 123]. The frequency
of GAS diseases has increased in the past two decades, reaching 7-10 cases per 100,000 in the US
and Canada [6, 7]. A large number of circulating serotypes pose a significant challenge for the
vaccine approach, with none approved to date [125, 126]. Without a vaccine, the burden of GAS
sequelae and invasive diseases is extreme, and the need for improved means to prevent and manage
infections is high.
GAS is an iron-requiring pathogen that mostly relies on heme-iron to satisfy its need for
the metal [89]. Proteins involved in heme capture and import are critical for GAS survival in the
host. The sia operon encodes a key heme acquisition pathway in GAS, including two surface
receptors and an ABC transporter, which capture heme from the host (shr) shuttle it across the cell
wall (shp) and through the cytoplasmic membrane (siaABC) [30, 33, 34, 71, 72]. Shr, the first
receptor in the sia heme relay, binds to hemoglobin and other host hemoproteins [72]. It is a 145
kDa surface protein with a unique N-terminal region (NTR) followed by two near–iron transport
(NEAT) domains [30]. Shr binds to hemoglobin using a novel mechanism through a domain
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(DUF1533) that appears twice in its NTR; this new hemoglobin binding module was named HID
for Hemoglobin-interacting domain [30, 32]. Following binding to hemoglobin, NEAT1 captures
and transfers the heme to either NEAT2 or Shp [33, 127]. Inactivation of shr impairs the bacteria's
ability to grow on hemoglobin as a sole source of iron [30] or in human blood [86]. In addition to
its contribution to the iron acquisition, Shr binds fibronectin and laminin in vitro [57], and deletion
mutants show reduced binding to fibronectin or laminin in a strain-dependent manner [57, 86,
128]. Shr knockout mutants are attenuated in both zebrafish [57], and mouse models for invasive
GAS infections [86].
The essential role Shr plays in GAS pathophysiology raised the possibility of targeting this
protein for the development of antibacterial strategies. Immunizing mice intraperitoneally with the
purified protein or intranasally with Shr-expressing Lactococcus lactis protects from an invasive
GAS infection [92]. Moreover, rabbit Shr-antiserum administrated prophylactically also defends
against GAS in a mouse model for passive immunity [92]. In this study, we used a B-lymphocyte
screen to identify two native human monoclonal antibodies (TRL96 and TRL186) to Shr. Here,
we show that TRL186, but not TRL96, aids in the clearance of systemic GAS infections in both
prophylactic and therapeutic mouse models and elucidate its defense mechanism.
4.2

Materials and methods
4.2.1

Strains and growth conditions

The strains and plasmids used in this study are listed in Table 5. Escherichia coli were
grown aerobically in Luria-Bertani broth at 37°C. GAS and Streptococcus dysgalactiae subsp.
equisimilis (SDSE) were grown statically at 37C in Todd-Hewitt broth (Difco Laboratories) with
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0.2% w/v yeast extract. When necessary, ampicillin (100 µg/mL), or kanamycin (70 µg/mL) was
added to the medium.
Table 5 Strains and plasmids used in this study
Name

Description

Reference

Host for pCB1 and pEB11
Host for pHSL2 and pYSH6
M type 1,
M type 49, mtsR-

Invitrogen
Invitrogen
Lab stock
Lab stock
ATCC# 12388

Expresses His6-Xpress-ShrGAS from PBAD
Expresses Strep-tag-NTR from Ptet
Expresses Strep tag-NEAT2 from Ptet
Expresses His6-MBP-NEAT1 from Ptac
Expresses His6-Shrdys from PT7

[72]
[30]
[33]
[33]
[129]

Strains
E. coli BL21 Star™DE3
E. coli One shot Omni Max2-TI
GAS MGAS5005
ZE491
S. dysgalactiae
subsp. equisimilis
Plasmids
pCB1
pEB10
pHSL2
pYSH6
pYSH9

4.2.2

Single B-lymphocyte mAb discovery technology

Blood samples were collected from anonymized donors under informed consent approved
by the Institutional Review Board of Stanford University (Stanford Blood Center, Stanford, CA),
and peripheral mononuclear cells were prepared as described. Using the CellSpot platform (Trellis
Bioscience, Redwood City, CA) [130], memory B cells were stimulated to proliferate and
differentiate into plasma cells. The secreted IgG footprint (100 fg/cell over a 5-h period) of
individual cells was probed with fluorescent nanoparticles of distinguishable types conjugated with
full-length recombinant Shr protein, the NEAT1 and NEAT2 domains, and BSA (counterscreening bead). Over 30 mAbs have been cloned based on their binding profiles. The V regions
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from mRNA of single B-cells of interest were cloned onto an IgG1 constant region, which was
then expressed by transient transfection in HEK293 cells.
4.2.3

Enzyme-linked immunosorbent assays (ELISA)
4.2.3.1 ELISA with Shr proteins

Full-length Shr from GAS (ShrGAS) or SDSE (Shrdys), and ShrGAS fragments (NTR,
NEAT1, or NEAT2) were expressed in E. coli and purified using affinity chromatography as
previously described [30]. Antibody binding to the target was evaluated by ELISA using 96-well
EIA/RIA microplates (Corning™ Costar™). Microplates were incubated overnight at 4°C with 25
µg/mL bait protein in PBS (10 mM phosphate-buffered saline, 100 nM NaCl, pH 7.4). Wells
coated with BSA, and uncoated wells served as controls for nonspecific interactions. Plates were
washed with PBS and 0.05% Tween (PBST), blocked with 5% soymilk (in PBST) for one hour at
37°C and washed again. TRL186 (2 µg/mL in PBST) was allowed to react with the bait for one
hour at 37°C. Antibody binding was detected using alkaline phosphatase (AP) conjugated antihuman IgG (Sigma). The absorbance at 405 nm was measured after 30 min incubation at room
temperature after the addition of p-nitrophenyl phosphate hexahydrate disodium salt (pNPP)
tablets dissolved in diethanolamine buffer solution (KPL). For affinity testing, TRL186 (in PBST)
was added to a plate coated with ShrGAS. Binding was detected using horseradish peroxidaseconjugated anti-human IgG.
4.2.3.2 ELISA with synthetic peptides
A library of overlapping peptides (15-mers with an offset of three amino acids)
encompassing ShrGAS NTR (Mimotopes, Melbourne Australia) were screened for interactions with
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TRL186 by ELISA similar to that done with Shr proteins. Biotinylated peptides dissolved in 80%
DMSO (5-15 mg/mL) were diluted 1/200 in PBST and immobilized onto Pierce streptavidincoated high capacity plates (Thermo ScientificTM). TRL186 (2 µg/mL in PBST) was allowed to
interact with the coated wells for 30 minutes at room temperature, and binding was detected using
AP-conjugated anti-human IgG.
4.2.3.3 ELISA with immobilized bacteria
Overnight grown cultures (5 mL of OD600 0.9) of GAS or SDSE were harvested, washed
with PBS (5 mL), and used to coat microplates (50 µL) overnight at 4°C. After blocking, TRL186
was allowed to interact with the coated wells for one hour at 37°C and binding was detected as
above.
4.2.3.4 ELISA with ShrGAS and hemoglobin
Human hemoglobin (Sigma) was biotinylated using the EZ-Link™Sulfo-NHS-SSBiotinylation Kit (Thermo ScientificTM) according to manufacturer’s instruction. Microplates were
coated overnight at 4°C with purified Shr or control proteins. Plates were washed and blocked as
above, and biotinylated hemoglobin (50 nM in saline) was allowed to react with the coated wells
during overnight incubation at 4°C. Hemoglobin binding was detected with streptavidinconjugated AP (Sigma). The same assay was used to study the impact of TRL186 on Shr’s binding
to hemoglobin, only that mAb in increasing concentrations was allowed to interact with the coated
wells for 1 hour at 37°C, before the addition of the biotinylated hemoglobin.
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4.2.4

GAS growth in hemoglobin and mAb

THYB containing 3 mM 2,2’ dipyridyl (DP, Acros Organics) with 5 µM hemoglobin and
20 µg/mL antibody (TRL186 or TRL96) were inoculated with overnight GAS cultures (starting
OD600 0.01). The culture optical density was determined following 20-hour incubation at 37°C.
4.2.5

Growth and differentiation of HL60 cells

HL60 promyelocytic leukemia cells were purchased from the American Type Culture
Collection (CCL240); they were maintained, passaged, and differentiated into granulocytes (with
100 mM dimethylformamide [DMF]) as described [131]. The viability of the differentiated cells
was assessed using trypan blue exclusion and was considered acceptable if more than 90% of the
cells excluded the azo dye. HL60 cells were used for opsonophagocytic assay at day five postdifferentiation as long as the expression of CD35 (complement receptor 1) was up-regulated by ≥
55% of the cell population and that of CD71 (transferrin receptor) was down-regulated by ≤ 15%
of the cell population, as determined by flow cytometry (BD LSRFortessaTM) [132, 133].
4.2.6

Opsonophagocytosis Killing Assay (OPKA)

GAS opsonization was evaluated using a previously described method [131, 134]. Briefly,
mAbs diluted in Hanks balanced salt solution containing 0.1% gelatin (OPA buffer) was added to
a 96-well microplate (10 µL/well). 20 µL of GAS culture (50 CFU/µL) and 10 µL of 50% baby
rabbit serum or normal rabbit sera (NRS, control group) were added to wells, and the plates were
incubated at 37 °C for 30 minutes on an orbital shaker at 200 rpm. 40 µL of differentiated HL60
cells (1x104/µL) freshly prepared in OPA buffer was added, and the plates were incubated at 37
°C for an additional 45 minutes with shaking. 40 µl from each reaction was mixed with 360 µL of
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0.9% NaCl and plated on THYA plates (100 µL/ plate) to enumerate the colony number.
Opsonophagocytic killing was calculated as following equation: (CFU [control] - CFU [mAb])/
CFU [control]) * 100.
4.2.7

Passive vaccination and GAS infection model

MGAS5005 cells were harvested at the mid-logarithmic phase (OD600 0.7), washed, and
resuspended at the desired density in 0.9% saline. Bacterial concentration was determined by
microscopic counts and verified by plating. CD-1 mice (20–22 g, Charles River Laboratories) were
infected by intraperitoneal (IP) injection of 0.1 mL cell suspension. Mice were weighed and
administrated IP with a single dose of TRL186 (15 mg/kg) or with PBS (mock vaccination) one
hour before challenge with 5 × 107 CFU (prophylactic model) or four hours after infection with 1
x 108 CFU (therapeutic model). Fifteen mice were used in experimental groups with at least one
repeat. Mice were observed four times per day after the challenge. Morbid animals were euthanized
according to protocols approved by the Georgia State University Institutional Animal Care and
Use Committee.
4.2.8

Structural Prediction

The DUF1 domain was modeled with Modeller [135]. The structure of DUF2 domain
(PBD: 6DK) was used as a template [32]. RAMPAGE was used to verify that structural residues
resided primarily in the favored region (98%), with only a few in the allowed region (2%) and that
no residues resided in the outlier region [136].
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4.2.9

Statistical Analysis

Data presented are averaged from experiments repeated at least twice (Student’s t-test, P ˂
0.05). The survival curve was analyzed by Kaplan-Meier plots.
4.3

Results
We selected two lead candidates, TRL96 and TRL186, based on high specificity and

affinity to Shr and investigated their efficacy in protection against GAS infection.
4.3.1

TRL96 and TRL186 bind to GAS surface and enhance opsonization

To examine if TRL96 and TRL186 interact with GAS surface, we performed a whole-cell
ELISA, where GAS cells were used to coat the microtiter plates and allowed to react with the
mAbs (Figure 15A). Both mAbs generated specific and significant binding with S. pyogenes cells
with a stronger signal for TRL186 (OD405 0.7), providing nearly half the signal as the positive
control polyclonal antibodies, anti-Shr and anti-GAS. Since both mAbs interacted with whole
cells, it indicates that the epitopes for TRL96 and TRL186 on Shr were accessible on the GAS
surface.
Next, we performed OPKA to measure the ability of the mAbs to opsonize GAS cells.
There was a marked reduction in GAS survival in the presence of both antibodies; in contrast, no
killing was observed while using the normal rabbit serum (NRS) control. The mAbs enhanced
opsonophagocytic killing by 44% for TRL96, and 35% by TRL186 (Figure 15B).
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Figure 15 TRL96 and TRL186 bind to whole-cell and enhance opsonization
A. Microtiter wells coated with ZE491 strain of GAS were reacted with mAbs and antibody
binding was detected. Data are from two experiments done in triplicates B. GAS cells (1000 CFU)
preincubated with mAbs or NRS in 50% baby rabbit serum were added to HL60 cells. GAS
survival after 30 min incubation was determined by measuring colony forming units. Data were
derived from three experiments. The standard deviation (SD) is represented by the error bars.
4.3.2

TRL186 protects mice from invasive GAS infection

We evaluated the in vivo efficacy of the mAbs in a prophylactic model against systemic
GAS infection (Figure 16A). A single dose of each mAb (15 mg/kg) was administered
intraperitoneally into the mice of the experimental groups, while the control groups received the
same volume of PBS. After one hour, we infected the mice with a mid-dose of MGAS5005 (107
CFU), and then monitored survival for five days. TRL186 conferred 100% protection to the mice.
In contrast, mice receiving TRL96 were as susceptible as the control group. This observation
implicates TRL186 in GAS protection while eliminating TRL96 from further analysis.
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To explore the protection conferred by TRL186, we tested the therapeutic effectiveness
(Figure 16B). CD-1 mice were first infected with a lethal dose of MGAS5005 (108 CFU), and the
mAb was injected four hours after exposure. We observed a rapid progression of GAS infection
in the control mice, which resulted in only 27% survival after five days. In contrast, mice that
received TRL186 had a 73% survival rate. Together, the immunity conferred by TRL186 in both
infection models suggests its potential utility in infection treatment.

Figure 16 TRL186 protects mice from GAS infection
A. Prophylaxis of TRL96 and TRL186, B. Therapeutic efficacy of TRL186. Mice (N=15) were
injected intraperitoneally with mAb (15 mg/kg) one hour before infection (A, 5x107 CFU) or four
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hours after infection (B, 1x108 CFU) with MGAS5005. The data shown are pooled data from two
independent experiments.
4.3.3

TRL186 interacts with a short segment in the NTR of Shr

An ELISA with immobilized Shr showed that TRL186 binds to the full-length Shr with
high potency (KD is in the 100 pM range, Figure 17A). We next performed an ELISA with Shr
fragments to identify the binding site of TRL186. The Shr variants include recombinant proteins
with just the NTR, the NEAT1 domain, or the NEAT2 domain (Figure 17B). TRL186 generated
a strong binding signal with the NTR fragment similar to the positive control, full-length Shr, while
only background signals were recorded from the wells containing NEAT1 or NEAT2. To define
the epitope region on the NTR recognized by TRL186, we constructed a series of overlapping
peptides covering Shr-NTR comprising biotin-labeled 15-mers peptides with 12 overlapping
amino acids in each peptide. Among 109 peptides covering the Shr-NTR region, only two peptides
(#33 and #34) exhibited significant reactivity with TRL186 in an ELISA (Figure 17C). This
analysis identified a short Shr segment (IKKGDKVTFISA) located at the end of the first
DUF1533/HID region in the interaction with TRL186, which we mapped onto the predicted ribbon
structure (Figure 17D).

73

Figure 17 TRL186 affinity and binding site
A. TRL186 binds to Shr with high affinity. Microtiter plate wells coated with Shr were allowed
to react with TRL186 in serial dilution starting at 5 ug/ml (30 nM). Antibody binding was plotted
as a function of TRL186 concentration. B. TRL186 binding is localized to Shr-NTR. TRL186
was allowed to interact with wells coated with the full length Shr, NTR, NEAT1 (N1), or NEAT2
(N2). C. TRL186 binds to peptides from Shr-NTR. TRL186 was allowed to react with
immobilized peptides derived from NTR. The reaction in wells without antibody (no Ab), uncoated
wells (PBS), or BSA coated wells (BSA) is shown. The data are pooled from three independent
experiments. Error bars represent SD. The top panel in C shows a schematic representation of Shr.
The black arrow indicates the TRL186 binding site. D. Ribbon diagram of predicted DUF 1533
structure. The first DUF1533 region is shown in blue, and the TRL186 binding location is in red.

74
4.3.4

TRL186 interferes with NTR-hemoglobin binding and hemoglobin-

dependent growth of GAS
Since the NTR region is known to interact with hemoglobin, we examined the Shrhemoglobin interaction in the presence of TRL186 in an ELISA. After optimizing the hemoglobin
binding by purified NTR protein (Figure 18A), we evaluated the NTR-hemoglobin binding in the
presence of increasing concentrations of TRL186. Hemoglobin binding by NTR was inhibited in
a dose-dependent manner by TRL186 (Figure 18B). The maximum inhibition (43%) was achieved
at 2 µg/mL concentration. The partial inhibition indicates that TRL186 did not block the entire
region on the NTR that interacts with the hemoglobin.
Next, we tested if TRL186 impacts the bacteria’s use of hemoglobin as a sole source of
iron (Figure 18C). We added TRL186 in THYB chelated with DP and supplemented with
hemoglobin. Overnight-grown GAS cells (starting OD600 0.01) were then added to investigate the
antibody-mediated inhibition in heme iron uptake. We used TRL96 as a negative control since it
binds to the NEAT1 domain (data not shown), which does not interact with hemoglobin [30]. 5
µM hemoglobin was sufficient for partial restoration of the GAS only culture and the TRL96
control. However, cultures grown with TRL186 did not exhibit restoration. Our data suggest that
TRL186 prevents streptococci from interacting with hemoglobin and utilizing it as an iron source.
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Figure 18 Impact of NTR-hemoglobin binding and hemoglobin-dependent growth in the
presence of TRL186
NTR was allowed to react with biotin-labeled hemoglobin in the absence (A) or presence (B) of
TRL186. AP-conjugated streptavidin was used to detect the Shr/hemoglobin interaction at 405 nm.
Inhibition of hemoglobin binding (%) is plotted as a function of TRL186 concentration. C. NZ131
GAS cells were inoculated into THYB, iron-chelated THYB (DP), or THYB-DP supplemented
with hemoglobin (Hb) with and without TRL186 or TRL96. Growth was monitored at 600 nm.
Data are from two independent experiments done in duplicates. Error bars represent SD.
4.3.5

TRL186 interacts with whole-cell and purified Shr of S. dysgalactiae

Shr from GAS and SDSE have almost identical sequences in the TRL186 binding region
(Figure 19A). Therefore, we investigated the interaction of TRL186 in a whole-cell ELISA with
SDSE (Figure 19B) and recombinant ShrSDSE similar to that done with GAS cells and ShrGAS
(Figure 19C). We recorded a strong binding signal in both cases, which suggests that the mAb
also recognized Shr on the SDSE surface.
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Figure 19 TRL186 interacts with SDSE cells and Shr protein
A. Sequence alignment of TRL186 binding site in ShrGAS (WP_010922617.1) and ShrDys
(BAH82346.1). The grey area indicates the border of the first DUF 1533. Microtiter plate wells
coated with SDSE (B) or ShrDYS protein (C) were allowed to react with TRL186, and antibody
binding was detected. The reaction in wells without antibody (no Ab) or uncoated wells (PBS) is
shown. Each bar represents an average of three repeats, and SD is represented by the error bars.
4.4

Discussion
Herein, we report a high-affinity mAb against Shr, which protects from systemic GAS

infection in mice. This is the first human mAb described against a protein involved in GAS heme
acquisition. In this study, we used a single B-lymphocyte technology to isolate a pool of mAbs
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against GAS-Shr. Based on affinity to Shr, we selected two lead candidates (TRL96 and TRL186)
for further characterization.
Shr is exposed on the streptococcal surface [57]. Our whole-cell ELISA with mAbs
revealed that the epitopes on Shr are accessible on the surface and recognized by the mAbs (Figure
15A). Opsonophagocytic killing is a potent mechanism by which many bacterial surface-specific
mAbs act to reduce bacterial load [137]. We previously showed that Shr antiserum evokes
opsonizing antibodies that facilitate phagocytosis [92]. In a complement-mediated opsonization
reaction, we observed both TRL96 and TRL186 enhanced GAS clearance, which suggests their
potential in treatment (Figure 15B). Next, we investigated the ability of each mAb to protect mice
in a prophylactic analysis. Prophylaxis with TRL96 conferred no protection to mice infected with
GAS, while, TRL186 bestowed 100% protection (Figure 16A). Since TRL96 did not aid in
protecting from GAS infection, we only tested TLR186 for its therapeutic value (Figure 16B).
Mice that were given TRL186 four hours after exposure to GAS were almost 50% more likely to
survive than mice given PBS. These protection data are encouraging since protection by antibody
administrated after a challenge can be more difficult to achieve compared to a pre-challenge
vaccination especially, in a model for aggressive systemic infection, as we used in this study.
Prophylaxis with a human mAb to the hemoprotein receptor IsdB of Staphylococcus aureus, for
example, confers significant protection in a lethal sepsis model, but not when given after the
challenge [138]. Notably, the same IsdB mAb is protective in a staphylococcal catheter
colonization model when administrated either pre- or post-infection. Together, the opsonic
efficacy and protective potential suggest utility for TRL186 in the antibody-mediated treatment
against the GAS disease.
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Shr is a large surface protein that belongs to the GAS core genome. To better understand
the mechanism of TRL186 in vivo protection, we investigated the antibody binding region. An
ELISA indicated that the antibody binds the NTR (Figure 17B). The region was further narrowed
using overlapping peptide sequences to identify a short sequence (IKKGDKVTFISA) at the end
of the first DUF1533 region (Figure 17C). Using the protein prediction software, Modeller, we
generated a ribbon structure of this region (Figure 17D). The antibody binding location appears
to be at the end of the antiparallel β-sheet directly, a region that was recently recognized for
interacting with hemoglobin [32].
The interactions between bacterial receptors and host hemoproteins consist of the first step
in the process of heme uptake, in the case of Shr, this step is mediated by its NTR. A recent study
extends the hemoglobin-capture mechanism by showing that two domains of unknown function
(DUF1533) in the NTR, now named hemoglobin-interacting domains, bind hemoglobin
independently [32]. Based on TRL186 binding region, it is reasonable to assume that the mAb is
blocking Shr interaction with hemoglobin. We tested the ability of hemoglobin to bind to purified
Shr in the presence of the mAb, and found that TRL186 inhibited NTR-hemoglobin binding in a
concentration-dependent manner (Figure 18B). This observation raised the possibility that
TRL186 interferes with heme uptake. The addition of hemoglobin or hemoglobin with TRL96
(control), to medium containing DP, which chelates free but not heme iron [139], restored GAS
growth. In contrast, with TRL186, GAS growth remained inhibited, similarly to the DP only group
(Figure 18C). These observations indicate that at least a part of TRL186 protection is due to the
iron-starvation of the bacteria. Together, these data suggest that TRL186 offers protection by
interfering with the heme intake. Notably, TRL96, which could not defend from GAS infection,
had no impact on heme uptake. TRL186 may also offer protection against the recently recognized
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emerging pathogen S. dysgalactiae, as the mAb showed specific reactivity with both whole-cells
and purified ShrSDSE (Figure 19).
Because of the central role of iron in infection, the iron uptake machinery is an attractive
vaccination target. Cattle vaccination against a siderophore receptor, for example, reduced the load
of E. coli 0157 in feces and the rectoanal mucosa [140, 141]. Heme acquisition satisfies the iron
requirement for GAS, and each of the heme uptake components characterized in GAS contributes
to virulence [36, 57, 86, 93, 142, 143]. Therefore, an antibody-mediated treatment impacting heme
intake may offer a promising treatment strategy. Blocking heme uptake is a significant part of the
protection mechanism against S. aureus provided by human mAbs against the heme receptor, IsdA
[144]. Redundancy often limits protection by an antibody that targets a single antigen [145], and
using an antibody cocktail improved efficacy and strain coverage in several models for
staphylococcal infections [146]. Hence, a combination therapy that consists of several mAbs that
may include the heme receptors Shp [71] and HupY [93], and the binding protein SiaA (HtsA)
[72] might increase the protection observed with TRL186.
Altogether, the data show that TRL186 elicited significant protection in mouse models,
achieved by both opsonization and heme-blocking. Because TRL186's target antigen, Shr, belongs
to the core genome of GAS and a few additional streptococci [30], it could be a therapeutic
candidate with broad efficacy. The prevalence of antibiotic resistance places an urgent demand for
new antimicrobial means. The recent strides in antibody discovery and engineering enabled the
isolation of therapeutic antibodies candidate to treated infection by major bacterial pathogens,
including S. aureus, Bacillus anthracis, and Clostridium difficile [145, 147-149]. Only a few
protective mAbs were described in GAS. One recent example includes a mAb to the PlateletActivating Factor Acetylhydrolase, SsE. Prophylaxis with an anti-SsE mAb increased neutrophil

80
infiltration, reduced lesion size, and systemic spread in mice challenged subcutaneously with the
invasive MGAS5005 GAS strain [150]. To the best of our knowledge, TRL186 is the first mAb
that increases mouse survival rate in a model for systemic GAS infection in a therapeutic mode.
This study serves as a proof of concept for using mAbs that target heme uptake in GAS for
immunotherapy.
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5 CONCLUSIONS
GAS causes a wide variety of clinical manifestations through its arsenal of virulence factors
and the ability to evade the host immune system. Incidence of antibiotic resistance and the
emergence of new virulent strains further complicate the prevention and control of GAS infections.
This dissertation intended to improve the understanding of heme uptake and its implications on
bacterial physiology and disease. The investigations focused on GAS and related Gram-positive
pathogens. The knowledge gained could then be used and for the development of new prevention
and therapy.
Iron requiring pathogens employ different strategies for scavenging the metal from the
host’s restricted iron environment to survive and mount an infection. Previous studies from this
lab showed that iron is essential for GAS growth, and heme satisfies most of its iron requirement
as GAS is unable to utilize transferrin and lactoferrin [89]. This research group and others have
established that Sia heme-relay proteins are involved in GAS virulence [30, 33, 34, 36, 57, 72, 86,
90-92, 117-119]. These findings demonstrate that the components of the heme acquisition
pathways are critical virulence factors in the β-hemolytic GAS. This dissertation identified a new
receptor and importer that are needed for GAS heme uptake and delineate their contribution in
pathophysiology. The study also described human monoclonal antibodies that target the
hemoprotein receptor, Shr, their efficacy, and protection mechanism.
The gene we named in this study, hupY, encodes a cell surface receptor that belongs to the
core genome of GAS and the related vaginal colonizer and pathogen GBS [144]. Similar proteins
promote adherence in other bacteria. Previous studies in GBS and GAS demonstrate that HupY is
a protective antigen and that GAS expresses the hupY gene during infection [59-61]. This
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dissertation describes the function of HupY and its role in GAS biology. The data identified
receptor HupY as a new heme receptor, which promotes the acquisition of iron from hemoglobin
and heme. HupY does not have a NEAT domain or any of the canonical motifs usually found in
heme-binding proteins. HupY LRR (Leucine-rich repeat [80]) is the only common element it
shares with some heme receptors, such as Shr (GAS) [30], IlsA (B. cereus) [151] and Hal (B.
anthracis) [152]. Hence, HupY mediates heme capture by a novel mechanism. Additional studies
are needed to determine how the cell-wall protein, HupY, transfer the heme into the cell. HupY
may deliver its heme to one or more of the receptor proteins or the heme transporters encoded by
the sia operon. It is also possible that HupY uses an independent pathway. Experiments in a murine
model demonstrated that HupY serves a significant role in GAS and GBS colonization of the
vaginal track. Together, these observations illustrate the important part of the iron and heme uptake
proteins in the establishment of infection investigations in GAS, and related pathogens.
Shr, Shp, and SiaABC together play a significant role in heme capture and relay in GAS,
but the function of the remaining siaDEFGH genes in the 10-gene sia operon was not described
before this work. This investigation elaborated on the role of the last three genes, siaFGH, in iron
homeostasis and virulence in GAS. The data established that SiaFGH is a new type of heme
importer that contributes to GAS growth on heme iron and that this importer is imperative for both
bacterial colonization and invasive infections. The SiaFGH proteins are highly conserved in GAS
isolates, and the related S. dysgalactiae and S. equi, and homologous systems can be found in the
genomes of additional Gram-positive bacteria, including important pathogens. Hence, the
description if the SiaFGH function has broad impactions on bacterial physiology overall.
Furthermore, conventional ABC transporters are the only type of heme importers that were
described up to date [36, 72, 153]. The findings of an ECF heme transporter in this dissertation are
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therefore novel and expands the paradigm of heme transport in bacteria overall. This investigation
did aim at the import mechanism of the SiaFGH system, and additional studies are needed to
examine this.
Shr, the first protein in the sia operon, is the only GAS protein shown to scavenge heme
from host proteins. This dissertation used murine infection models to investigate the efficacy of
human monoclonal antibodies (mAbs) against Shr. The experiments identified the monoclonal
antibody, TRL186, as a high-affinity antibody that protects from invasive GAS infections. The
data show that TRL186 binds near the hemoglobin-binding region of Shr and intervenes with
hemoglobin binding by the purified receptor and in heme uptake by whole GAS cells. TRL186 is
the first human mAb described against GAS protein involved in heme uptake. Shr (with the entire
sia operon) is highly conserved among GAS isolates and Streptococci spices that harbor the
operon. Hence, targeting Shr may avert the strain-diversity and cross-reactivity problems found
with the M- based vaccines, and could facilitate protection against also from related streptococci.
In summary, this dissertation elaborates on the mechanisms for heme uptake, and their role
in bacterial physiology and infection in GAS and related pathogens. The investigations
demonstrated that targeting heme uptake proteins has the premise of yielding an effective treatment
with broad protection for Streptococcal diseases.
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Disclaimer: I, Nilanjana Chatterjee, conceived and contributed to the design and implementation
of the research described in this dissertation. We wrote three manuscripts based on these findings
with consultation with Dr. Zehava Eichenbaum and additional co-authors. In chapter one, I was
responsible for investigating HupY binding to heme and the receptor role in GAS iron hemostasis
and heme uptake. In Chapter II, constructed the complemented strain and conducted the
experiments investigating the role of the SiaFGH proteins in GAS use of hemoproteins as an iron
source and in heme import. In Chapter III, I determined TRL186 binding site, the antibody impact
on hemoglobin binding by Shr and the use of hemoglobin iron by GAS, and its interactions with
the S. dysgalactiae cells and proteins.

85
APPENDICES
Appendix A: Supplemental Tables
Appendix A.1 (Table S1: Differentially expressed genes (FDR <0.05) between WT
NZ131 GAS grown in liquid culture (CDM) to bacteria colonizing the murine vaginal
tract (Mouse))
Locus

spy49_0020

Name

purC

Description

Phosphoribosylaminoimidazole-

WT_Mouse/

WT_Mouse/

WT_CDM

WT_CDM:

Fold change

FDR

-17.79689279

3.9252E-27

-14.96843173

2.97204E-35

succinocarboxamide synthetase
spy49_0021

purL

Phosphoribosylformylglycinamidine
synthase

spy49_0022

purF

Amidophosphoribosyltransferase

-12.64638665

3.59039E-21

spy49_0023

purM

Phosphoribosylglycinamide cyclo-ligase

-12.26483359

2.11743E-11

spy49_0024

purN

Phosphoribosylglycinamide

-8.577561355

2.34114E-13

-12.95265693

8.39393E-17

formyltransferase
spy49_0025

purH

Bifunctional purine biosynthesis protein
PurH

spy49_0027

purD

Phosphoribosylamine-glycine ligase

-11.7123065

1.3817E-26

spy49_0028

purE

Phosphoribosyl

-10.62375203

1.32574E-16

-11.45309502

2.47934E-19

Hypothetical

-2.647293277

0.026089987

carboxyaminoimidazole

mutase
spy49_0029

purK

Phosphoribosylaminoimidazole
carboxylase

spy49_0030
spy49_0031

purB

Adenylosuccinate lyase

-2.618810105

8.84673E-05

spy49_0032

comR

Cro/CI family transcriptional regulator

-2.440317465

0.017118775

spy49_0038

adhE

Bifunctional

40.12663315

2.72862E-12

acetaldehyde-CoA/alcohol

dehydrogenase
spy49_0039

adhP

Alcohol dehydrogenase

94.85044562

1.03862E-12

spy49_0044

rpsJ

SSU ribosomal protein S10p

-1.855981459

0.045601753

spy49_0046

rplD

LSU ribosomal protein L4p

-1.699724911

0.033931423

spy49_0059

rplE

LSU ribosomal protein L5p

-1.598571362

0.0434377
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spy49_0067

rplO

LSU ribosomal protein L15p

-1.63057787

0.034983464

spy49_0068

secY

Preprotein translocase secY

-1.533273042

0.035611777

spy49_0069

adk

Adenylate kinase

-1.843282338

0.005791335

spy49_0073

rpsK

SSU ribosomal protein S11p

-1.798205748

0.015699409

spy49_0075

rplQ

LSU ribosomal protein L17p

-1.801846444

0.04175526

4-diphosphocytidyl-2-c-methyl d-erythritol

-2.841871511

0.000144147

-2.118752295

0.010434288

3.493505965

0.035513787

-4.213243931

7.59761E-05

spy49_0078

kinase
spy49_0079

4-diphosphocytidyl-2-c-methyl d-erythritol
kinase

spy49_0083c

Histidine triad protein

spy49_0089

Dipicolinate

Synthase,

DNA

binding

protein
spy49_0092

comYC

Putative competence protein

-16.71045907

0.016579383

spy49_0100

proC

Pyrroline-5-carboxylate reductase

2.241261205

0.008183834

spy49_0110c

hslO

-2.291765805

0.004435282

spy49_0111

nra

Regulatory protein

4.628441583

0.002364207

spy49_0112

cbp

Putative collagen binding protein

28.8277752

0.000101273

spy49_0113

lepA-1

Putative signal peptidase I

27.6303236

4.76209E-05

spy49_0114

cpa

Hypothetical, pilin related, sortase B signal

128.5972146

9.6656E-10

domain
spy49_0116

srtB

NPQTN specific sortase B

22.87148797

0.000114638

spy49_0117

cpa

Hypothetical

40.38676901

9.06581E-08

spy49_0122c

Transcriptional regulator

263.0986236

1.54749E-07

spy49_0126c

Transcriptional regulator

6.058603003

8.01847E-07

spy49_0127

Translation initiation inhibitor

9.566704208

2.89342E-11

Hypothetical, regulatory protein

23.16943635

1.50834E-14

Hypothetical

313.6976398

2.18755E-09

spy49_0128

sloR

spy49_0129
spy49_0130

ntpI

ATP synthase subunit I

150.3667367

1.35913E-18

spy49_0131

ntpK

V-type ATP synthase subunit K

313.6976398

2.35748E-08

spy49_0132

ntpE

V-type ATP synthease subunit

114.1300285

1.69506E-12

spy49_0133

ntpC

V-type ATP synthase subunit C, oxidative

69.38875564

4.58367E-11

phosphorylation
spy49_0134

ntpG

ATP synthase subunit F

56.18408362

1.2191E-08

spy49_0135

ntpA

V-type ATP synthase alpha chain

40.10153977

1.013E-14

spy49_0136

ntpB

V-type ATP synthase beta chain

55.30885223

3.20593E-15

spy49_0137

ntpD

V-type ATP synthase subunit D

40.23104119

3.68502E-13

Toxic anion resistance protein

3.033703084

0.000899301

spy49_0138c
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spy49_0139c

Hypothetical

3.103681

0.012784526

spy49_0142

ABC transporter

-2.765488792

3.33971E-06

spy49_0151

metB

Cystathionine beta-lyase

3.73154311

2.02844E-05

spy49_0153

sgaT

Putative transport protein SgaT

606.9991739

5.42321E-11

spy49_0154

sgaB

PTS ascorbate transporter subunit IIB

33.37336365

1.35964E-06

spy49_0155

ptsN, ptxA,

PTS ascorbate transporter subunit IIA

35.70261679

2.98188E-07

sgbH

3-keto-L-gulonate-6-phosphate

410.1262563

4.89557E-09

ulaD

decarboxylase

spy49_0157

sgaU, ulaE

L-xylulose 5-phosphate 3-epimerase

57.40443854

4.54118E-09

spy49_0158

araD, ulaF

L-ribulose-5-phosphate 4-epimerase

86.22549306

1.58141E-10

L-ascorbate 6-phosphate lactonase

22.51462851

5.25408E-15

L-proline glycine betaine ABC transporter

-5.833824633

0.003122534

-5.09235192

9.29565E-05

Hypothetical

2.131357095

0.005961916

ulaC
spy49_0156

spy49_0160
spy49_0161

opuAA

ATP-binding protein ProV
spy49_0162

opuABC

L-proline glycine betaine ABC transporter
ATP-binding protein ProW

spy49_0169
spy49_0189c

rofA.1

RofA family transcriptional regulator

4.789738816

0.000220758

spy49_0199

dut

Putative deoxyuridine 5-triphosphate

-2.97990095

7.48104E-06

spy49_0200

radA

RadA-like DNA repair protein

-2.683417358

2.92959E-06

Carbonic anhydrase

-5.035620936

3.87769E-14

2-

17.77032209

2.38442E-09

Sugar ABC transporter substrate-binding

14.96071212

5.90162E-12

13.30723644

1.79798E-06

Sugar ABC transporter permease

7.78110658

2.57923E-05

Hypothetical

13.56989279

3.65965E-06

N-actylneuraminate lyase

16.02702835

1.05476E-11

spy49_0217

Glucose kinase

14.76841001

7.97692E-09

spy49_0235c

Hypothetical

256.8005765

1.12348E-05

spy49_0201
spy49_0211

nanE

N-acetylmannosamine-6-phosphate
epimerase

spy49_0212

ugpB

protein
spy49_0213

ugpA

Acetylneuraminate

ABC

Transporter

permease
spy49_0214

ugpE

spy49_0215
spy49_0216

nanH

spy49_0242

sufC

Iron-sulfur cluster assembly ATPase SufC

-3.557084614

2.3767E-07

spy49_0243

sufD

Iron-sulfur cluster assembly protein SufD

-3.987508443

1.66502E-08

Cysteine desulfurase

-3.433696287

9.07E-05

-3.544303086

1.66629E-06

spy49_0244
spy49_0245

iscU

Iron-sulfer
protein IscU

cluster

assembly

scaffold
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spy49_0246

sufB

Iron-sulfur cluster assembly protein SufB

-4.962278409

1.73095E-12

spy49_0247

pbp7

D-alanyl-D-alanine carboxypeptidase

2.404750289

0.005649303

spy49_0248c

dacA

Penicillin-binding

2.577022024

0.000123799

-1.84699643

0.040912596

-1.774885871

0.017791308

protein

7

precursor

(PBP-7)
spy49_0259

Hypothetical

spy49_0263

Ubiquinone/menaquinone

biosynthesis

methyltransferase
spy49_0266

atmA

ABC transporter substrate-binding protein

-4.40073042

6.17997E-06

spy49_0276

lemA

Putative cytoplasmic membrane protein

-1.929674868

0.021429456

spy49_0285

snf

Putative SNF helicase

-1.960588728

0.004339213

Hypothetical

-1.70055663

0.026351913

spy49_0294
spy49_0307

ypaA

Riboflavin transporter YpaA

5.589643132

0.042798679

spy49_0315

fhuG

Ferrichrome transport system permease

2.778052575

0.003898829

4.805916585

5.61368E-05

protein
spy49_0316

fhuB1

Ferrichrome transporter system permease
protein

spy49_0317c

fhuD

Ferrichrome-binding periplasmid protein

4.654451381

0.000282152

spy49_0318

fhuC1

Ferrichrome transport ATP-binding protein

3.754058259

0.000789101

Arsenate reductase

2.296610224

0.031503076

spy49_0333
spy49_0335

lctO

L-Lactate oxidase

10.65140536

5.03718E-05

spy49_0336

prtS/spyCEP

Putative cell envelope proteinase

-3.180660552

0.004038505

Hypothetical

6.757159823

9.34231E-06

Ribonucleotide reductase of class Ib

432.0269702

3.57468E-27

spy49_0337
spy49_0339

nrdF.2

(aerobic) beta subunit
spy49_0340

nrdI

Ribonucleotide

reductase

stimulatory

1079.152582

6.23852E-20

Ribonucleotide-diphosphate

reductase

245.7685672

1.7568E-29

protein
spy49_0341

nrdE.2

subunit alpha
spy49_0356c

Hypothetical

-8.262593067

0.048523277

spy49_0357c

Hypothetical

-16.78897341

0.017320633

spy49_0367c

Hypothetical

-8.139490927

0.040423558

spy49_0374

glpT

Glycerol-3-phosphate transporter

5.846010406

2.07713E-08

spy49_0381

mtsA

Metal ABC transporter substrate-binding

6.225597117

1.13969E-19

spy49_0382

mtsB

ATP-binding protein MtsB

1.827231797

0.016788616

spy49_0383

mtsC

Integral membrane protein MtsC, ABC

2.242106502

0.007912867

-2.006082652

0.000703334

transporter
spy49_0390

pyrH

Uridylate kinase
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spy49_0392

S1 RNA binding domain

-2.074646658

0.000199685

spy49_0398

Myosin-cross-reactive antigen

3.047540798

0.019125795

Putative

-1.989138114

0.002280657

spy49_0399

phoH

phosphate

starvation-induced

protein
spy49_0422

vacB

Putative exoribonuclease R

-2.010225372

0.001037552

spy49_0429c

gloA

Lactoylglutathione lyase

2.122292641

0.011968273

NAD(P)H-flavin oxidoreductase

2.029883409

0.033945217

spy49_0430c
spy49_0431c

pepQ

Putative Xaa-Pro dipeptidase

1.852149736

0.048568566

spy49_0432

ccpA

Catabolite control protein A

2.389637168

0.001379918

spy49_0436

tagH

Teichoic acid export ATP-binding protein

12.78393915

8.83258E-06

TagH
spy49_0437

Hypothetical

4.852984544

0.003439383

spy49_0438

Hypothetical

4.858786638

0.001798229

-2.324807158

0.013422537

spy49_0447

rnc

Ribonuclease

III,

dsRNA-specific

ribonuclease
spy49_0448

smc

Putative chromosome segragation SMC

-2.088613951

0.01056393

spy49_0484

bglG

Putative transcription antiterminator

3.991470691

0.012679178

Putative PTS system, beta-glucosides-

5.426753754

0.002361019

spy49_0485

specific IIABC component
spy49_0487

bglA

Putative beta-glucosidase

4.739245828

0.000345994

spy49_0494

ptsK

HPr kinase phophorylase

-1.772587802

0.013037954

spy49_0495

lgt

Prolipoprotein diacylglyceryl transferase

-1.751382547

0.011828264

spy49_0508c

Endolysin, phage associated

3.385651366

0.019482521

spy49_0509

ABC transporter, permease subunit of

-7.513391597

1.83805E-06

Hypothetical

-2.852711513

0.019125795

cbiOQ-type, hypothetical
spy49_0510
spy49_0513

ppc

Phosphoenolpyruvate carboxylase

-1.680603992

0.033751335

spy49_0525c

agaD

Putative PTS dependent galactosamine IID

7.466091353

0.034597322

spy49_0526c

agaW

Putative

7.500027807

0.024671471

PTS

dependent

N-acetyl-

galactosamine IIC componenet
spy49_0528c

ugl

Putative unsaturated glucuronyl hydrolase

4.646690433

0.034731292

spy49_0533

kdgA

4-hydroxy-2-oxoglutarate

4.01709345

0.035225821

aldolase/2-

dehydro-3-deoxyphosphogluconate
aldolase
spy49_0540

fabG

Acetoin reductase

2.499154266

0.010360527

spy49_0541

dinG

DNA polymerase III, epsilon subunit/ATP-

1.806011875

0.044914097

dependent helicase
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spy49_0548

pepD

Probable dipeptidase A

2.302864213

0.020088445

spy49_0549

adcA

Zinc-binding protein adcA precursor

10.70996959

0.001727165

GntR family transcriptional regulator

1.972463719

0.036814652

Putative

2.934968062

0.000319433

spy49_0550
spy49_0551

agaS

tagatose-6-phosphate

aldose/ketose
spy49_0559

Phosphoglycolate phosphatase

-1.840691557

0.00349562

spy49_0564c

Transposon

5.878670267

9.22313E-05

spy49_0565c

Transposase

3.76663936

0.024020115

spy49_0566c

RofA family transcriptional regulator

7.266108739

4.90031E-07

spy49_0568

sagA

Streptolysin S associated protein SagA

32.15204399

6.25566E-14

spy49_0569

sagB

Streptolysin associated protein SagB

21.60066817

7.06213E-13

spy49_0570

sagC

Streptolysin associate protein SagC

22.18914609

4.90734E-14

spy49_0572

sagD

Streptolysin associated protein SagD

23.53155986

8.19461E-14

spy49_0573

sagE

Streptolysin associated protein SagE

26.66151094

2.50249E-11

spy49_0574

sagF

Streptolysin associated protein SagF

20.47607079

1.84002E-13

spy49_0575

sagG

SLS export ATP-binding protein SagG

13.77946268

6.25566E-14

spy49_0576

sagH

SLS export transmembrane protein SagH

19.05169381

1.29496E-12

spy49_0577

sagI

SLS export protein SagI

19.64803067

2.27917E-18

spy49_0582

F0F1 ATP synthase subunit C

-2.333301581

0.013057482

spy49_0583

F0F1 ATP synthase subunit A

-2.062037626

0.001848147

spy49_0584

F0F1 ATP synthase subunit B

-1.747488406

0.021019874

spy49_0587

F0F1 ATP synthase subunit Gamma

-1.785796558

0.024878338

spy49_0588

F0F1 ATP synthase subunit Beta

-1.731788201

0.027174456

DNA-entry nuclease fragment

-2.20039985

0.024816975

Pseudogene

-2.139981014

0.031310712

Phenylalanyl-tRNA synthetase alpha chain

-1.954764996

0.046662575

spy49_0600

Hypothetical

-3.036551696

0.002364207

spy49_0601

ABC transporter ATP-binding protein

-3.671097568

9.80299E-10

Putative

-2.321413584

0.034983464

2.403523837

0.001170307

1.872334713

0.018284724

-2.20048541

0.014963993

2.320597814

0.000331948

2.088415886

0.013841151

spy49_0593

endA

spy49_0594
spy49_0596

spy49_0607c

pheS

mscL

large

conductance

mechanosensitive channel
spy49_0638c

folC.2

Deihydrofolate
synthase/folylpolyglutamate synthase

spy49_0642

Hypothetical

spy49_0646

Capsular

polysaccharide

biosynthetsis

regulatory protein
spy49_0651

pyrP

spy49_0652

pyrB

Putative uracil permease
Aspartate carbamoyltransferase
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spy49_0653

carA

Carbamoyl-phosphate synthase small chain

1.863465029

0.007522449

spy49_0661

hupY

Cell surface protein, MtsR repressed

27.25598866

1.07219E-21

spy49_0662

hupZ

Regulatory

37.6885773

8.39393E-17

2.296115394

0.000614135

protein,

heme

utilization

protein, MtsR-repressed
spy49_0669

pfoR

Putative regulatory protein, possible toxin
regulator

spy49_0671

apbA

2-dehydropantoate 2-reductase

2.608263631

0.000408468

spy49_0672

fruR

Putative transcipriotnal repressor

3.83192317

0.002044836

spy49_0673

fruK

Tagatose-6-phosphate

1-

4.422714519

0.000789101

PTS system, fructoase-specific IIABC

3.035252732

0.004176921

kinase

pohsphofructokinase
spy49_0674

fruA

component
spy49_0686c

5-nucleotidase

-5.323517253

1.27582E-07

spy49_0689

Two component sensor histidine kinase

1.894947547

0.011582364

spy49_0690

mvaK1

Mevalonate kinase

-1.595389928

0.042419206

spy49_0696

thyA

Thymidylate synthase

-1.749802494

0.034983464

spy49_0697

dyr

Dihydrofolate reductase

-1.851828525

0.00977296

spy49_0701

engB

GTP-binding protein EngB

-1.659524049

0.031188118

spy49_0712

pyrF

Orotidine 5-phosphate decarboxylase

5.354968508

0.003379324

spy49_0713

pyrE

Orotate phosphoribosyltransferase

4.376429356

0.001210992

ABC trasnporter

-3.628258265

8.11082E-09

Amino acid ABC transporter permease

-3.269312297

8.74686E-08

-1.913304699

0.017909501

-2.105047717

0.007891447

spy49_0715
spy49_0716

yckA

yckA
spy49_0717

ung

Uracil-DNA glycosylase

spy49_0722

bcaT

Branched-chain

amino

acid

aminotransferase
spy49_0725c

Hypothetical

-7.116583756

6.75192E-10

spy49_0726

Hypothetical

-6.088512285

7.22378E-07

spy49_0727

Hypothetical

-4.766727359

6.43354E-05

Single stranded DNA specific exonuclease

-1.628379165

0.038274324

spy49_0735

recJ

recJ
spy49_0737

dnaD

DNA replication protein

-1.874747386

0.005084225

spy49_0738

nth

Endonuclease III

-1.635075702

0.042419206

spy49_0746c

Prophage ps2 integrase

4.205086167

0.010665396

spy49_0747c

Hypothetical

5.715224159

0.000258304

spy49_0748c

Phage-associated protein

2.761791092

0.018956537

spy49_0749c

Repressor phage associated

3.086746726

0.010666067
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spy49_0750

Hypothetical

-15.86305232

3.18298E-05

spy49_0751c

Hypothetical

2.960409688

0.033945217

spy49_0752

Phage DNA-binding anti-repressor protein

-48.0403898

1.8283E-05

spy49_0753

Phage excisionase

-8.616417275

0.007461577

spy49_0755

Hypothetical protein

-10.14593276

0.024671471

spy49_0756

Hypothetical

-11.42452997

0.000137999

spy49_0759

Phage associate protein, hypothetical

-18.51940234

2.17911E-08

spy49_0760

Phage-associated protein

-19.08183987

1.29496E-12

spy49_0761

Phage associate protein, hypothetical

-12.46355741

1.93284E-09

spy49_0762

Bacteriophage-type DNA polymerase

-43.99589661

2.85587E-09

spy49_0763

DNA primase/helicase Phage associated

-19.52280751

5.16224E-10

spy49_0765

Phage associated helicase

-47.94535003

1.40334E-09

spy49_0766

Hypothetical

-11.03377912

0.001164427

spy49_0767

Phage associated transcriptional activator

-25.86810101

6.28156E-05

spy49_0768

Phage terminase small subunit

-27.15730197

0.003444264

spy49_0769

Phage terminase large subunit

-72.65214123

3.31639E-15

spy49_0770

Phage portal protein

-25.09495611

6.21429E-13

spy49_0771

Phage associate protein, hypothetical

-254.4361957

3.97929E-17

spy49_0772

Putative phage associated protein

-184.7148826

1.74276E-13

spy49_0773

Phage scaffold protein, hypothetical

-88.12464903

4.836E-16

spy49_0774

Hypothetical phage, major head protein

-108.6673651

2.86999E-16

spy49_0775

Hypothetical phage protein

-88.17792193

2.289E-09

spy49_0776

Hypothetical phage protein

-127.04592

1.39206E-10

spy49_0777

Hypothetical

-68.91028783

4.94274E-15

spy49_0778

Hypothetical phage protein

-192.1943446

9.1468E-12

spy49_0779

Hypothetical phage protein

-152.4505395

4.68091E-14

spy49_0780

Phage associate protein, hypothetical

-84.0216645

1.13644E-11

spy49_0781

Putative phage associated protein

-27.82531338

4.16193E-05

spy49_0782

Phage associate protein, hypothetical

-75.03119465

3.57E-13

spy49_0783

Phage associate protein, hypothetical

-68.40416421

6.94022E-11

spy49_0784

Phage associated protein

-54.56162604

6.73744E-11

spy49_0785

Phage hyaluronidase

-36.82409233

8.80808E-15

spy49_0788

Hypothetical

-50.70878832

2.81011E-10

spy49_0789

Phage associated holin

-68.47589395

1.7247E-12

spy49_0790

Cell wall hydrolase

-51.51289336

1.38618E-09

Streptococcal pyrogenic exotoxin H

-48.95184061

0.00018136

ABC transporter substrate-binding protein

-2.725069393

0.002021338

spy49_0792
spy49_0797

speH
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spy49_0799

ABC transport protein

-2.722868678

0.007986381

spy49_0800

Putative ABC transporter system ATP-

-2.746529236

0.01281917

binding protein
spy49_0803

estA

Tributyrin esterase

-1.841984595

0.004712627

spy49_0807

acoA

Pyruvate dehydrogenase E1 component

-4.665429853

3.30519E-08

-4.116077938

5.11083E-07

-3.659765614

1.8283E-05

alpha
spy49_0808

acoB

Pyruvate dehydrogenase E1 component
beta

spy49_0809

acoC

Dihydrolipoamide

acetyltransferase

component of pyruvate dehydrogenase
complex
spy49_0810

acoL

Dihydrolipoamide dehydrogenase

-3.217580783

8.01017E-05

spy49_0819

hemN

Coproporphyrinogen III oxidase, oxygen-

-2.26199892

0.003823167

Acyl-AC thioesterase

-2.290878853

0.005097765

Peptide methionine sulfoxide reductase

-3.055962036

0.021098697

PTS Mannose transporter subunit IIA

6.451100515

0.003633704

independent
spy49_0820
spy49_0831

csrA, msrB

msrB
spy49_0833
spy49_0834

manX, ptsA

PTS sorbose transporter subunit IIB, kinase

37.08893398

1.56007E-08

spy49_0835

manY, ptsB

PTS Mannose transporter subunit IIC,

73.82399305

4.18523E-10

PTS Mannose transporter subunit IID

50.11562252

6.86673E-16

Succinate-semialdehyde

3.117562043

0.000100792

transporter
spy49_0836

manZ, ptsC

spy49_0841

dehydrogenase

NADP+
spy49_0842

uvrC

Putative excinuclease ABC

1.879303671

0.028973212

spy49_0850c

pgdA2

Polysaccharide deacetylase

2.719240483

0.007338216

spy49_0851

folC1

Dihydrofolate synthase/folylpolyglutamate

-2.234330951

0.012025362

4.066748445

0.005026719

7.443618691

5.03718E-05

14.90127796

1.61878E-05

29.75196646

1.85098E-07

synthase
spy49_0861c

citA

Putative two-component response regulator
of citrate/malate metabolism

spy49_0862c

citB

Putative two-component histidine kinase
regulator of citrate/malate metabolism

spy49_0863

malP

L-malate permease

spy49_0864

sfcA

Malate

dehydrogenase,

pyruvate

metabolism
spy49_0865c

tdh

Alcohol dehydrogenase, zinc-containing

46.56033856

1.63792E-09

spy49_0866

aphA

Acid phosphatase

7.738101403

2.88469E-08
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spy49_0867

eriC

Voltage-gated chloride channel family

-2.26753101

0.001444832

-2.882532158

0.006737777

-2.145792252

0.006671851

Hypothetical

-4.005479982

0.00014365

L-proline glycine betaine ABC transport

-1.666774299

0.037836445

-2.232805443

0.000144147

protein
spy49_0868

tesA

spy49_0871c

Putative platelet activating factor
Glutamine

amidotransferase,

class

I

predicted
spy49_0882c
spy49_0883

proV

ATP-binding protein
spy49_0884

proX

L-proline glycine betaine binding ABC
transporter protein / osmotic adaptation

spy49_0885

guaB

GMP reductase

-2.181839836

0.026089987

spy49_0888

uraA

Xanthine permease

-8.221235311

1.01149E-10

spy49_0893

tdk

Thymidine kinase

-1.985605635

0.011968273

spy49_0894

prfA

Peptide chain release factor 1

-2.30321357

0.000492223

spy49_0895

hemK

Putative protoporphyrinogen oxidase

-2.513544205

4.38133E-05

Hypothetical

-2.046855884

0.002436412

Serine hydroxymethyltransferase

-1.983019785

0.001120622

spy49_0899

Hypothetical

-1.736549073

0.022738984

spy49_0900

Pneumococcal

-1.974422991

0.007100475

-2.19622152

8.04067E-05

spy49_0897
spy49_0898

glyA

vaccine

antigen

A-like

protein
spy49_0901

mdlB

ABC transporter, ATP-binding/permease
protein

spy49_0902

mdlB

Putative ABC transporter

-2.248073163

0.000160656

spy49_0903

nox1

NADH oxidase

-2.024908245

0.00119981

spy49_0908

Hypothetical

-2.24075808

0.025340448

spy49_0909c

Hypothetical

-1.874446132

0.007998265

spy49_0910c

hlyIII

Putative hemolysin III

-2.706223469

0.031856136

spy49_0920

satD

Putative acid tolerance SatD-like protein

2.629643215

0.00921343

Hypothetical (with 0920)

2.189528764

0.024671471

2-(5-triphosphoribosyl)-3-

2.010103009

0.026197044

spy49_0921
spy49_0927c

citG

dephosphocoenzyme-A synthase
spy49_0928c

gntR

Transcriptional regulator, GntR family

2.529038773

0.018530699

spy49_0929c

citM

Citrate transporter

180.3183757

2.35748E-08

spy49_0933

oadB

Oxaloactetate decarboxylase beta chain

3.450846803

0.046199775

spy49_0934

citD

Putative citrate lyase, gamma subunit

24.91386645

0.034282888

spy49_0936

citE

Citrate lyase beta chain

6.858722692

0.0015172

spy49_0937

citF

Citrate lyase alpha chain

5.76456311

0.000625878
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spy49_0938

citX

Probably apo-citrate lyase phosphoribosyl-

15.11182782

0.001383202

10.54152762

0.000119483

dephospho-CoA transferase
spy49_0939

oadA

Methylmalonyl-CoA decarboxylase alpha
chain

spy49_0949

guaA

GMP synthase - glutamine--hydrolyzing

-1.93012536

0.002770622

spy49_0952c

uup

ABC transporter, ATP-binding protein

2.188226876

0.010360527

spy49_0955

ar08

Putative transcriptional regulator/amino

3.288233982

0.017529591

Putative anaerobic ribonucleotide reductase

-2.260231629

0.029331598

transferase
spy49_0957c
spy49_0958c

cls

Cardiolipin synthetase

-5.040102022

6.37712E-10

spy49_0959c

fhs1

Putative formate-tetrahydrofolate ligase

-7.860783756

3.47495E-23

spy49_0960c

lplA

Lipoate-protein ligase A

-2.459314707

0.000319433

spy49_0961c

Hypothetical

-2.770318673

2.06533E-06

spy49_0962c

Hypothetical

-2.88342636

1.95796E-06

spy49_0963c

Glycin cleavage system H protein

-2.742336987

9.98796E-05

spy49_0964c

Hypothetical

-2.422993345

0.000287506

spy49_0965c

nemA

Putative trimethylamine dehydrogenase

-2.592908629

1.97077E-05

spy49_0966c

lplA

Lipoate-protein ligase A

-2.509925798

0.02105516

spy49_0968

dfp

Phosphopantothenoylcysteine

2.479455893

0.010360527

Hypothetical

2.468507087

0.047892353

decarboxylase
spy49_0969
spy49_0970

pgmA

Phosphoglucomutase

1.767496761

0.032108872

spy49_0979c

ciaH

Putative histidine kinase protein

1.978119987

0.034282888

Riboflavin

-1.963730642

0.014956362

tRNA pseudouridine 55 synthase

-1.930949352

0.001185382

Hypothetical

-1.782797608

0.045601753

Putative ABC transporter, permease protein

2.44760198

0.006250833

spy49_1000c

Putative transcriptional regulator

-1.681991057

0.009554571

spy49_1004c

Hypothetical

-2.253749551

0.038486879

spy49_1005c

Hypothetical

-2.387656596

0.032091677

spy49_1006c

Hypothetical

-3.185898137

0.003047678

spy49_0992c

kinase/FMN

adenylyltransferase
spy49_0993c

truB

spy49_0994c
spy49_0997c

salY

spy49_1008

alsT

Putative amino acid symporter

-4.349013372

6.27314E-05

spy49_1010c

cfa

CAMP factor

82.84636014

2.65555E-27

spy49_1014c

phnA

Hypothetical

-1.947383574

0.048265786

spy49_1017c

pyk

Putative pyruvate kinase

-1.639083476

0.020510501

spy49_1018c

pfk

6-phosphofructokinase

-2.124634218

0.001983442
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spy49_1019c

dnaE

DNA polymerase III alpha subunit

-2.002784373

0.002037038

spy49_1025c

glgP

Maltodextrin Phosphorylase

21.58386151

1.63831E-08

spy49_1026c

malQ

4-alpha-glucanotransferase

18.18852952

9.82702E-08

spy49_1027c

malR

Putative maltose operon transcriptional

2.826093806

0.000384846

15.46352092

2.49416E-08

repressor
spy49_1028

malE

Maltose maltodextrin ABC transporter
substrate binding protein

spy49_1029

malF

Maltose ABC transporter permease

20.27905927

7.12456E-07

spy49_1030

malG

Maltose ABC transporter permease

31.15558597

1.66502E-08

Hypothetical

33.29123811

0.014667452

spy49_1042c
spy49_1043c

celB

Putative PTS system IIC component

6.986453731

0.002105406

spy49_1047c

bglG

Putative transcription antiterminator

13.12540796

0.000195228

Hypothetical

48.22881506

0.001170307

Ribosyl nicotinamide transporter, pnuC-

9.150465023

6.6551E-08

Diaminopimelate epimerase, hypothetical

22.77316828

1.05654E-10

spy49_1048c
spy49_1050

pnuC

like protein
spy49_1065
spy49_1066c

uhpC

Hypothetical

4.021031983

0.001799862

spy49_1070c

paaI

Phenylacetic acid degradation protein

-2.766202786

0.000696465

spy49_1084c

inlA

Internalin

72.90151761

3.87777E-09

Hypothetical

-2.398325739

0.038069395

DNA polymerase III subunites gamma and

-2.392852078

4.38133E-05

Hypothetical

-3.348717103

7.6948E-06

spy49_1086c
spy49_1087c

dnaX

tau
spy49_1088c
spy49_1091

deaD2

Putative RNA helicase

2.401165224

0.015936478

spy49_1092c

pgdA1

Polysaccharide deacetylase family protein

1.906394237

0.016365217

spy49_1093c

gapN

Non-phosphorylated

-5.155698767

1.26091E-13

glyceraldehyde-3-

phosphate dehydrogenase (NADP)
spy49_1096

nrdH

Putative glutaredoxin

-2.429094123

0.007323837

spy49_1097

nrdE1

Ribonucleotide reductase of class Ib

-1.951876373

0.02105516

(aerobic) alpha subunit
spy49_1111c

uhpC

Oxalate:formate antiporter MFS transporter

-19.9198025

2.48375E-23

spy49_1113c

coiA

Putative transcription factor

3.130180199

0.025629671

spy49_1122c

sodM

Superoxide dismutase (Mn)

-6.801497329

1.54056E-08

Hypothetical

2.93651403

0.017118775

spy49_1129
spy49_1132c

deaD1

Putative ATP-dependent RNA helicase

-3.29149566

9.82702E-08

spy49_1140c

fdhC

Formate/nitrite transporter family member

4.624272461

1.57632E-07

spy49_1144

pyrD

Dihydroorotate dehydrogenase

-1.873912179

0.017529591
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spy49_1151c

Hypothetical surface protein, LPXTG-

1.669778078

0.021429456

13.35158803

3.1763E-19

motif cell wall anchor
spy49_1159c

manB

Phosphoglucomutase,
phosphomannomutase

spy49_1160c

phr

Putative deoxyribodipyrimidine photolyase

-2.020277826

0.012248332

spy49_1164

clpE

Putative ATP-dependent protease

-1.820392585

0.024964831

spy49_1173c

ftsZ

Cell division protein ftsZ

-1.700245027

0.040006861

spy49_1179c

typA

Putative GTP-binding protein

-2.129799525

0.000230236

spy49_1180c

pspB

Hypothetical

1.987194299

0.002254952

spy49_1181c

nagC

Glucokinase

1.691807564

0.034446745

spy49_1192c

arcC

Carbamate kinase

225.9117465

1.59788E-23

spy49_1193c

argE

Hypothetical, ArgE related

404.2111083

2.18777E-28

Hypothetical,

355.4907536

6.39761E-24

Ornithine carbamoyltransferase

241.2815319

3.11951E-19

Hypothetical, Acetyltransferase

611.8943636

2.40228E-22

spy49_1194c

Arginine:ornithine

antiporter, disrupted
spy49_1195c

arcB

spy49_1196c
spy49_1197c

arcA

Arginine deiminase

111.7202145

7.64226E-12

spy49_1198c

crp

Transcriptional regulator, CrP/Fnr family

4.845677777

5.56804E-07

spy49_1199

argR

Putative arginine repressor

17.04394215

9.93912E-09

spy49_1201c

mmcQ

Hypothetical

2.288159198

0.001070959

spy49_1202c

yesM

Putative two-component sensor histidine

2.718546552

0.00020817

kinase
spy49_1203c

yesN

Putative two-component response regulator

3.398321982

0.001028007

spy49_1204c

msrA1

Peptide methionine sulfoxide reducatese

79.40381568

2.32983E-10

spy49_1205c

bcp

Hypothetical, Dihydroneopterin aldolase,

21.00258457

2.24258E-05

related to Bcp
spy49_1206c

ccdA

Cytochrome C biogenesis protein

33.14663669

1.73956E-06

spy49_1208c

cas1

CRISPR-associated endonuclease Cas1

3.438513426

0.006096268

spy49_1213c

srmB

ATP-dependent RNA helicase SrmB

3.95687147

0.005943056

spy49_1225c

aroE1

Shikimate 5-dehydrognase

2.170894264

0.042344714

spy49_1226c

bgaA, lacZ

Beta-galactosidase

12.93419172

1.70254E-11

Putative two-component sensor response

8.351911231

3.61108E-07

8.070624862

2.23849E-10

Hypothetical

6.138142463

0.002283896

ABC transporter substrate-binding protein

141.1243538

1.22457E-13

spy49_1227c

regulator
spy49_1228c

Putative two-comonent sensor histidine
kinase

spy49_1229c
spy49_1230c

ugpB
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spy49_1231c

ugpE

Sugar ABC transporter permease

11.47418165

0.000591869

spy49_1233c

lplB

Sugar ABC transporter permease

19.46513739

3.58254E-06

spy49_1234

nagC

Putative transcriptional regulator

40.55615048

0.005929735

spy49_1235c

bglB

Beta-glucosidase

4.052081707

0.00023796

spy49_1236c

hyl

Putative hyaluronidase

4.473714091

0.000202509

spy49_1237c

purR

Putative transcritional regulator

3.22188338

0.010817526

Hypothetical

27.13718343

0.00027006

spy49_1238
spy49_1239

ams1

Alpha mannosidase

12.87685888

3.63221E-06

spy49_1240c

rocA

Putative histidine kinase protein

2.157932965

0.012679178

spy49_1247c

psrp-1

Ribosomal subunit interface protein

3.512530706

9.81664E-06

spy49_1248c

comF

Putative late competence protein

31.74915131

0.015256458

spy49_1251

cysM

Cysteine synthase

-14.24378964

8.86503E-06

spy49_1253c

cof

Hydrolase, haloacid dehalogenase family,

-1.925720276

0.006999703

Putative permease

2.132688736

0.044674748

Hypothetical

-1.938269457

0.001446396

cyclophilin type
spy49_1272

gntT

spy49_1275c
spy49_1281c

nadE

NAD synthetase

-1.76037966

0.004598548

spy49_1283c

aapA

Amino acid permease

-1.836140451

0.009472094

spy49_1284c

nox2

Thioredoxin reductase

-2.054306613

0.000261186

spy49_1286c

glnQ

Amino acid ABC transporter, ATP-binding

-7.031212455

1.08973E-09

protein
spy49_1287c

hisM

Putative amino acid ABC transporter

-5.392679784

5.27868E-13

spy49_1289c

srmB

Putative ATP-dependent RNA helicase

-2.29893595

4.13025E-05

Hypothetical

1.856821645

0.037310348

Transaldolase

25.03248199

3.61331E-13

Putative transcriptional regulatory protein

7.38130445

3.34235E-07

spy49_1297c
spy49_1301c

ptsH, tal

spy49_1303c
spy49_1304c

npx

Putative NADH peroxidase

5.314937219

2.29944E-06

spy49_1305c

glpF1

Glycerol uptake facilitator protein

5.943563644

0.016721871

Hypothetical

2.196646354

0.000345916

spy49_1312c
spy49_1313c

ara1

2,5-diketo-D-gluconic acid reductase

2.087374974

0.024816975

spy49_1318c

degV

Hypothetical

-4.529566708

3.8158E-11

spy49_1320c

cof

Hypothetical

2.171235436

0.001446396

Hypothetical

1.9229184

0.023858836

spy49_1321c
spy49_1322c

lacD1

Tagatose-bisphosphate aldolase

21.90628534

1.95885E-06

spy49_1323c

lacC1

Tagatose-6-phosphate kinase

26.18147717

0.019490032

57.39859142

0.008963751

spy49_1324c

Tagatose-6-phosphate
phosphofructokinase

kinase/1-
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spy49_1325c

lacB

Galactose-6-phosphate isomerase

spy49_1326c

lacA

Galactose-6-phosphate

isomerase

lacA

48.37565138

1.32099E-05

17.59736404

2.23575E-05

subunit
spy49_1327c

gatC

PTS galactitol transporter subunit IIC

49.69593237

1.80192E-09

spy49_1328c

sgaB

PTS fructose transporter subunit IIB

200.1925265

1.60185E-05

spy49_1329c

ptsN

PTS galactose transporter subunit IIA

23.55067819

6.54348E-05

spy49_1330

lacR1

Lactose

4.387289054

6.69503E-05

phosphotransferase

system

repressor
spy49_1336c

rbfA

Ribosome binding factor A

-

0.004176921

1.954391735
spy49_1337c

infB

Translation initiation factor 2

-

0.008838765

1.827952354
spy49_1340c

spy49_1346

nusA

hit

Transcription termination protein, NusA-

-

0.027174456

like

1.883770974

Putative cell-cycle regulation histidine triad

2.686616051

0.014740275

Hypothetical

4.165747937

0.000181155

protein
spy49_1347
spy49_1348c

lytR

Putative transcriptional regulator

-2.192877258

0.000384176

spy49_1349c

rimL

Histone acetyltransferase

-2.894235375

2.63385E-06

spy49_1350c

Hypothetical

-3.803393528

2.68599E-09

spy49_1351c

Hypothetical

-14.70667371

9.51827E-15

Acetyl-coenzyme A carboxylase carboxyl

-58.49370472

3.25485E-32

-58.39520559

3.25485E-32

-65.60029207

1.38446E-51

spy49_1359c

accA

transferase alpha
spy49_1360c

accD

Acetyl-coenzyme A carboxylase carboxyl
transferase beta

spy49_1361c

accC

Acetyl-Coa carboxylase biotin carboxylase

spy49_1362c

fabZ

3-hydroxyacyl-dehydratase,

acyl-carrier

protein
spy49_1363c

accB

Acetyl-CoA carboxylase biotin carboxyl
carrier protein subunit

spy49_1364c

fabF

3-oxoacyl-ACP synthase

-

1.08795E-36

60.8603585
-

1.47328E-33

63.82355684
-

5.50614E-54

76.74515658
spy49_1365c

fabG

3-oxoacyl-acyl-carrier protein reductase

-

1.67878E-31

14.52243017
spy49_1366c

fabD

ACP S-malonyltransferase

-

2.86019E-44

98.87776466
spy49_1367c

fabK

2-nitropropane dioxygenase

-106.102435

1.01143E-53
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spy49_1368c

acpP

Acyl carrier protein

-13.9283794

1.59313E-12

spy49_1369c

fabH

3-oxoacyl-ACP synthase

-22.68423

1.172E-27

spy49_1370c

fabT

MarR family transcriptional regulator

-25.53787578

3.12045E-27

spy49_1371c

phaB

enoyl-CoA hydratase

-60.41181526

2.78751E-39

spy49_1374c

dnaK

Chaperone protein

3.047815034

0.018032691

Putative N-acetyl-muramidase

3.032642656

3.3683E-05

spy49_1377c
spy49_1378c

vanY

D-alanyl-D-alanine carboxypeptidase

2.483130411

0.000494918

spy49_1379c

phoE

Phosphoglycerate mutase family

2.212101292

0.011061102

Aspartate aminotransferase

-1.700316671

0.041121424

spy49_1388c
spy49_1389

uspA

Universal stress response protein

3.936846647

0.000296809

spy49_1390c

cof

Hypothetical

-2.445358509

3.46888E-05

spy49_1395c

siaH

ECF transporter, A component

2.563668954

0.002828757

spy49_1396c

siaG

ECF transporter, T component

2.700265152

0.004640134

spy49_1397c

siaF

ECF transporter, S component

4.705517065

2.7169E-08

spy49_1398c

siaE

Putative ABC transporter

7.030614116

4.13488E-10

spy49_1400c

siaD

Putative ABC transporter

12.49346497

6.12148E-09

spy49_1401c

siaC

Heme ABC transporter, ATP-binding

15.67647343

4.87133E-07

spy49_1402c

siaB

Heme ABC transporter, permease

10.81538051

1.89066E-07

spy49_1403c

siaA

Heme ABC transporter, substrate-binding

20.57639598

3.84341E-08

spy49_1404c

shp

Streptococcal

**Annotated

hemoprotein

transport

protein

as combined
with
spy49_1403c

spy49_1405c

shr

Heme binding Fe3+ siderophore transport

25.46105991

4.08402E-12

protein
spy49_1407c

isp2

Immunogenic secreted protein

1.691973784

0.015898135

spy49_1409c

acpS

Holo-acyl-carrier protein synthase

-2.044186084

0.013057482

spy49_1413c

scrK

Fructokinase

21.98071921

0.000230236

spy49_1414c

endoS

Hypothetical,

endo-beta-N-

23.23737584

2.84998E-08

Putative sucrose-specific PTS permease,

3.046649468

0.002018734

acetylglucosaminidase
spy49_1415c

scrA

enzyme II
spy49_1423c

uvrA

UvrABC system protein A

-3.101023433

1.16801E-07

spy49_1430

mutY

A/G specific adenine glycosylase

-2.380481236

0.000723107

spy49_1432c

trx2

Thioredoxin reductase

-1.917244928

0.020002095

spy49_1442

pfl

Formate acetyltransferase

10.30261685

1.75947E-12

Putative repressor, phage associated

3.248837759

0.035611777

spy49_1453

101
spy49_1506c

DNA replication protein

-3.478315292

0.029125542

spy49_1526

Hypothetical

3.548844621

0.001352219

spy49_1529

Hypothetical, repressor protein

1.910511986

0.019293062

Prophage NZ131.3 probable integrase

2.44062093

0.010360527

Hypothetical

2.403727204

0.023528208

spy49_1530

dnaC

xerD

spy49_1531
spy49_1533c

soxR, merR

Transcriptional reguator, MerR family

5.329089802

1.8283E-05

spy49_1534c

dnaQ

Putative DNA polymerase III epsilon

8.378152135

0.00148635

subunit
spy49_1535c

Hypothetical

1.751985875

0.034597322

spy49_1538

Hypothetical

2.571530374

0.013902021

spy49_1540c

deoC

Deoxyribose-phosphate aldolase

4.840260857

2.22931E-08

spy49_1541c

nupC

Nucleoside permease nupC

4.52695301

7.33698E-07

spy49_1542c

udp

Uridine phosphorylase

4.553718221

4.57794E-07

spy49_1543

phnF, gntR

Transcriptional regulator, GntR family

11.71860152

1.15619E-10

spy49_1544

rpsN

SSU ribosomal protein S14p

23.74880893

8.6714E-05

spy49_1545c

gcp

Putative glycoprotein endopeptidase

-1.60542909

0.026197044

spy49_1546c

rimI

Ribosomal

S18p-alanine

-1.572330706

0.037310348

protease-like

-1.721184338

0.017320633

protein

acetyltransferase
spy49_1547c

Inactive

metal-dependent

protein, putative molecular chaperone
spy49_1550c

glnA

Glutamine synthetase

2.138390458

0.001962679

spy49_1551c

glnR

Putative transcriptional regulator

2.226394608

0.034446745

spy49_1555c

hflC

Hypersensitive-induced response protein-

-2.619201418

1.86134E-05

CTP synthase

-2.068073213

0.011968273

Hypothetical

-2.06658535

0.006132285

like protein
spy49_1561c

pyrG

spy49_1565c
spy49_1567c

thiD

Phosphomethylpyrimidine kinase

-1.735028555

0.008863426

spy49_1568c

truA

tRNA pseudouridine synthase A

-1.555154073

0.042440998

spy49_1574

hsdM

Putative

1.891056005

0.026718848

Hypothetical

66.80118719

0.003494663

type

I

site-specific

deoxyribonuclease
spy49_1575c
spy49_1583c

salA

Lantibiotic salivaricin A precursor

7.888489315

0.027435286

spy49_1584c

lacG

6-phospho-beta-galactosidase

26.25658359

2.73901E-05

spy49_1585c

lacE

PTS lactose transporter subunit IIBC

43.38347301

8.35821E-10

spy49_1586c

lacF

PTS

16.95876742

3.689E-05

33.9949957

1.99704E-06

system,

lactose-specific

IIA

component
spy49_1587c

lacD2

Tagatose 1,6-diphosphate aldolase
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spy49_1588c

lacC2

Tagatose-6-phsophate kinase

10.3781957

0.000747633

spy49_1589c

lacB2

Galactose-6-phosphate isomerase subunit

6.915812889

0.012750448

7.861614837

0.005652392

Hypothetical

-3.827437711

0.021337443

LacB
spy49_1590c

lacA2

Galactose-6-phosphate isomerase lacA2
subunit

spy49_1598c
spy49_1599c

degV

DegV-domain containing protein

-8.143391329

1.01115E-16

spy49_1601c

spoU

23s rRNA methyltransferase

-1.857616588

0.002343973

Hypothetical

-2.148782759

0.01283226

spy49_1602c
spy49_1609c

mipB

Hypothetical, transaldolase

38.17099218

1.12402E-10

spy49_1610c

ulaA, sgaT

PTS beta-glucoside transporter subunit

33.26382575

1.83405E-10

IIBC
spy49_1611c

sgaB

PTS maltose transporter subunit IIBC

122.7184284

1.34106E-05

spy49_1612c

bglG

PTS fructose transporter subunit IIA

20.38768527

6.75624E-09

spy49_1626c

pulA

Amylopullulanase,

10.57066254

1.56184E-07

15.66804303

7.87661E-07

4.130621343

0.000603266

Type

II

secretory

pathway, surface protein
spy49_1627c

dexB

Glucan 1,6 alpha glucosidase

spy49_1628c

msmK

Sugar

ABC

transporter,

ATP-binding

protein
spy49_1630

ska

Streptokinase

-7.56996973

1.77886E-06

spy49_1633c

sclA

Collagen-like surface protein

-4.351050979

0.005187232

spy49_1635c

rgfB

Hypothetical, transaldolase

47.66859929

5.75804E-08

spy49_1636c

rgfD

PTS glucose transporter subunit IIABC

30.02094187

7.85367E-11

Hypothetical

-1.986837026

0.003902288

spy49_1637c
spy49_1638c

prmA

Ribosomal protein L11 methyltransferase

-1.941057282

0.001558135

spy49_1640c

nudB

MutT/nudix family protein

-2.139225705

0.000750684

spy49_1641c

nudA

Hypothetical

-2.16596377

0.013300771

Hypothetical

-1.938710583

0.002283896

Anthranilate synthase

3.329538224

0.000139654

ATPase AAA family

2.188709437

0.00451878

spy49_1642c
spy49_1654

trpG

spy49_1655
spy49_1656

pai1

Pai1 protein

3.392473983

0.027879215

spy49_1657

adk, flaR

DNA topology modulation protein FlaR,

3.663728035

0.000354778

putative
spy49_1658c

Hypothetical

12.33569291

0.00088254

spy49_1659c

Hypothetical

11.22847913

9.41317E-06

Hypothetical, Histidine triad HIT protein

90.74322524

5.59299E-08

spy49_1666c

htpA
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spy49_1667c

lmb

Laminin-binding surface protein, possible

98.66845063

3.52318E-06

zinc receptor
spy49_1669c

scpA

C5a peptidase precursor

-2.873454883

0.001832438

spy49_1670c

ennX

EnnX protein

-4.650260935

0.014749085

spy49_1671c

emm49

Antiphagocytic M protein

-5.312780329

0.000399589

Fc-gamma receptor, membrane bound

4.579737457

9.68729E-05

spy49_1672c

metalloprotease
spy49_1675c

isp1

Immunogenic secreted protein

1.843988803

0.041691184

spy49_1676c

baeS

Two-component system histidine kinase

1.916836074

0.009420574

spy49_1684c

sof

Serum opacity factor, invasion of epithelial

-3.119944298

0.023784854

Foldase protein

144.6055099

7.4313E-17

Hypothetical

388.4682734

1.0215E-21

912.4167145

1.16891E-20

877.302944

8.25052E-11

cells
spy49_1687c

prsA2, ropA

spy49_1688c
spy49_1689c

spi

spi, SpeB protease inhibitor

spy49_1690c

speB

Streptococcal

cysteine

protease/streptococcal pyrogenic exotoxin
B
spy49_1691

ropB

Rgg-like transcription regulator

2.574026368

0.002182807

spy49_1692c

mf1

Streptodornase, mitogenic factor I

33.12348164

2.28785E-23

spy49_1695c

gldA

Glycerol dehydrogenase

32.02257611

4.06407E-17

spy49_1696c

mipB

Fructose-bisphosphate aldolase

45.16837549

3.68357E-12

spy49_1697c

pflD

Pyruvate formate-lyase

23.14568344

1.842E-11

spy49_1698c

celB

Putative cellobiose-specific IIC component

2057.870482

1.79875E-15

spy49_1699c

celA

PTS cellobiose transporter subunit IIB

455.3697644

5.64188E-10

spy49_1700c

celC

PTS cellobiose transporter subunit IIA

509.688244

1.22736E-12

spy49_1703

pflA

Pyruvate formate-lyase activating enzyme

5.421751513

2.57923E-05

spy49_1707c

tdcF

Putative translation initiation inhibitor

-2.224330789

0.019490032

spy49_1713

pepD

Dipeptidase

27.36644523

5.56782E-15

spy49_1715c

groEL

Heat shock protein 60 family chaperone

3.911111868

0.00285931

3.426481674

0.012248332

GroEL
spy49_1716c

groES

Heat shock protein 60 family co-chaperone
GroES

spy49_1719c

csp

Major cold-shock protein

-3.866690785

0.001558135

spy49_1723c

hutI

Imidazolonepropionase

188.493026

2.32983E-10

spy49_1724

hutU

Urocanate hydratease

285.8861059

1.26892E-09

spy49_1725

ftcD

Glutamate formiminotransferase

872.3619209

2.40343E-08
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spy49_1726

Sugar ABC transporter substrate binding

501.3313399

9.51866E-07

Formate-tetrahydrofolate ligase

1628.163098

4.18693E-10

Hypothetical

708.9504584

3.64792E-08

protein
spy49_1727

fhs2

spy49_1728
spy49_1729

potE

Amino acid permease

1214.642433

8.54024E-10

spy49_1730

hutH

Histidine ammonia lyase

1260.532264

6.75192E-10

spy49_1731

hutG

Formimidoylglutamase

65.76939255

1.06429E-10

spy49_1732c

LuxR family transcriptional regulator

23.90783049

7.55422E-14

spy49_1742

Hypothetical

3.355303788

0.006558367

Ribonucleotide reductase of class III

3.301192679

0.000193999

2.10290423

0.011124005

spy49_1747c

nrdD

anaerobic, large subunit
spy49_1748c

ccs4

Hypothetical competence-induced protein
Ccs4

spy49_1753c

recA

RecA protein

-1.649149643

0.036814652

spy49_1781

padR

PadR family transcriptional regulator

-17.2800362

0.000349799

spy49_1782

Hypothetical

-22.73548907

2.37523E-05

spy49_1783

Hypothetical, membrane protein

-16.68154616

7.46402E-05

spy49_1784c

Phage infection protein

4.449412095

0.004186831

Putative transcriptional regulator

43.04552065

0.008105739

DHH family protein

-1.806344977

0.011704247

spy49_1785

acrR

spy49_1790c
spy49_1794

sdhB

L-serine dehydratase, beta subunit

11.16538746

5.53127E-11

spy49_1795

sdhA

Serine dehydratase subunit alpha

9.721170804

2.03487E-09

spy49_1811c

glcU

Hypothetical

-2.159703997

0.010922519

Probable transposase for insert-like

9.633091252

0.000195228

spy49_1819c

sequence element IS1161
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Appendix A.2 (Table S2: Bacterial strains and plasmids used)
Strain Name

Description

Citation

NZ131

Wild-type Streptococcus pyogenes strain isolated

[154]

from

a

patient

with

post-streptococcal

glomerulonephritis
NZ131ΔhupY *

NZ131 ΔhupY::aphA3 KanR

This study

BH10C

E. coli cloning strain

[155]

E.coli BL21 Star

Host for pZZ1 expression

Invitrogen

Plasmid

Description

Citation

pFED760

pGh9-ISS1 deleted for insertion element by inverse

[105, 156]

PCR; temperature sensitive replication origin, ErmR

pJC159

pFED760 with ermB replaced with chloramphenicol

[62]

resistance marker cat, CmR

pOsKaR

Source of aphA3 KanR cassette

[157]

pJC303

pLZ12-Spec-based vector with recA constitutive

[158]

promoter upstream of multiple cloning site, SpecR

pLC007 **

hupY complementation plasmid, hupY inserted

This study

downstream of the recA promoter in pJC303

pET101/D-TOPO

Directional TOPO®TA cloning vector

Invitrogen
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pZZ1

pET101 based vector that expresses HupY-His tag

This study

from PT7
* Mutant is stable and does not require antibiotics for retention
** Plasmid is retained during overnight growth in liquid culture without the addition of
antibiotics

Appendix A.3 (Table S3: Cloning and qPCR primers)
Cloning primers
Primer

Description

Sequence

LC149

hupY Upstream S PstI

GACTGCAGAGCTTGTTGACTTAAAGTCA
ACA

LC150

hupY Upstream AS 2step

GTTATCATTTTTTCTCCTTAAATCAATTG
TGGTAAAACCTTTCTAAAAGCCAAC

LC151

hupY Downstream S 2step

GTTGGCTTTTAGAAAGGTTTTACCACAA
TTGATTTAAGGAGAAAAAATGATAAC

LC152

hupY Downstream AS NotI

AGGCGGCCGCCTTGGATGGTTAGCCATT
ATCATA

LC153

Plasmid AS MluI inv

ACGCGTATTGATTTAAGGAGAAAAAAT
GATAAC

LC154

Plasmid S MluI inv

ACGCGTTGTGGTAAAACCTTTCTAAAAG
CCAAC

LC184

GAS lrrG compl S Gibson

tgaaaaagattttggtaaggggcggccgcATGAAGAAA
CATCTTAAAACAG
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LC185

GAS lrrG compl AS Gibson

ataacctgaaggaagatctggatccTTAATATTTTTTC
TTTTTTATAGCAGTTATTAG

ZE435

hupY forward primer, TA CACCATGCACAATCAGGAAGTTTTT
cloning

ZE436

hupY

revers

primer,

TA TATTGCAGAGTGTCGTCCTCTATTCGTT

cloning

TTT

qPCR primers
LC060

gyrA S qPCR primer

CAATGGATGGGGATGGTG

LC061

gyrA AS qPCR primer

CGCTGGTAAAACAAGAGGTTC

LC082

proS S qPCR primer

TGAGTTTATTATGAAAGACGGCTATAG

LC083

proS AS qPCR primer

AATAGCTTCGTAAGCTTGACGATAATC

LC092

spy49_1781 S qPCR primer

TCAAAGAATCCACCCTCTATCC

LC093

spy49_1781 AS qPCR primer

CCCGAAGAAGTGACAGCATA

LC094

spy49_1782 S qPCR

AAGGAAGCTGCCAGTGAAAT

LC095

spy49_1782 AS qPCR

CAGCAATACGGGTAAAGCAA

LC192

hupY S qPCR primer

TACTGCAGGTAAAGCGTTGTT

LC193

hupY AS qPCR primer

GCCTTCTTGGTCACTAAAGCC

LC278

hupZ S qPCR primer

ACAAACCTGTAACCTAAAAG

LC279

hupZ AS qPCR primer

AAAGGTCAACCCAATATTGG
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Appendix B Supplemental figures
Appendix B.1 (figure S1: RNA Seq validation)

qRT-PCR data validated the RNASeq results. Quantitative RT-PCR was done on two genes shown
to be downregulated in the vaginal tract via RNASeq (spy49_1781 and spy49_1782). qPCR
showed that both genes were downregulated in the vaginal tract (darker bars), matching the
expression patterns obtained by RNA sequencing (lighter bars).
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Appendix B.2 (figure S2: Expression of hupZ)

Expression of hupZ is not affected by deletion of hupY in GAS or GBS. Quantitative RT-PCR was
done on replicate RNA samples collected from WT GAS and GBS strains as well as their isogenic
mutant ΔhupY strains. Comparison of hupZ transcription between the WT and mutant strains
showed no significant difference in the expression of hupZ, demonstrating that deletion
of hupY was nonpolar.
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